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Abstract 
 
PAX3 is a transcription factor. It plays a major role in the development of melanocytes in the 
embryo. As a result of alternative splicing, the gene gives rise to eight different transcripts 
which encode proteins that have differing structures and are therefore likely to activate 
different downstream target genes. The presence of post-translational modifications has 
also been shown to alter the functions of the proteins.  
PAX3 regulates the maintenance of undifferentiated melanoblasts and mediates pathways 
involved in proliferation, migration and survival. It has been shown to be expressed in 
melanoblasts, adult melanocytes, naevi and in most melanoma cells. This implies that PAX3 
may be involved in such regulatory pathways in all of these cell types including melanoma. 
Melanoma is a notoriously aggressive and drug resistant form of skin cancer. Research into 
the role of PAX3 in melanoma could provide novel treatment options for targeted therapies 
aimed at PAX3 or its regulatory pathways.  
Therefore, in this study, the expression profile of PAX3 alternate transcripts was compared 
in normal melanocytes and melanoma cells. Moreover, differences in post-translational 
modifications between these cell types were assessed, as were changes in downstream 
target genes. This research further clarifies the role of PAX3 in melanoma and details the 
differences in its role here, relative to that in melanocytes. 
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1. Introduction 
 
Cutaneous Malignant Melanoma (from here on referred to as melanoma) is a skin cancer 
that arises from normal skin melanocytes. Studies have shown that the expression of the 
developmental gene, PAX3, is required for neural crest cells to commit to the melanocyte 
lineage and for proliferation. PAX3 is expressed across all cells of the melanocytic lineage, 
including the cells of naevi and melanoma. Furthermore, PAX3 has been shown to 
differentially regulate downstream target genes in melanoma cells compared to 
melanocytes. Thus further research into the role of PAX3 in melanocytes and melanoma 
cells is required in order to assess whether PAX3 is involved in key cellular processes that 
drive melanomagenesis and whether these pathways differ from those in melanocytes.  
2. Literature review 
 
The most aggressive form of skin cancer is cutaneous melanoma (Chin et al., 2006). 
Melanoma is responsible for only 4% of skin cancers, but accounts for 80% of deaths from 
skin cancer (Lewis et al., 2005). Moreover, metastatic melanoma is highly resistant to most 
drug therapies, making it difficult to treat (Chen et al., 2006; Chin et al., 2006). Melanoma is 
the most common cancer in people aged 15-39 years and the third most common cancer in 
people aged 40 years and above and is more frequent in males than in females (Threlfall and 
Thompson, 2010). Over ten thousand new cases are diagnosed every year in Australia 
(Cancer Council Australia, 2012).  
Melanoma is categorised clinically into Tumour, Node, Metastasis (TNM) stages 0, I, II, III 
and IV. During early stage melanoma (stages 0, I and II) the tumour is confined to the 
epidermal and dermal layers of the skin. At this point, the lesion can be excised from the 
skin. For patients with early stage melanoma, the 5-year survival rate is 95% (Balch et al., 
2009). As the disease progresses the tumour cells migrate through the underlying layers of 
skin and can invade blood and lymph vessels, allowing the aberrant cells to travel 
throughout the body and establish secondary tumours. For patients with advanced stage 
metastatic melanoma the 5-year survival rate drops significantly to below 45% (Balch et al., 
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2009). Currently, there are limited safe and effective treatment options available for 
metastatic melanoma (reviewed in Mackiewicz-Wysocka et al., 2013). This highlights the 
importance of further investigations into the mechanisms behind melanoma formation and 
progression so that an effective treatment focussed on inhibiting the pathways involved in 
disease progression can be developed.  
The paired box 3 gene (PAX3 in humans, Pax3 in mice) plays a crucial role in specification, 
proliferation and migration of melanocytes in the embryo (Bang et al., 1997; Goulding et al., 
1991; Hornyak et al., 2001). PAX3 continues to be expressed in normal melanocytes of the 
adult epidermis and is also expressed in naevi and melanoma cells (He et al., 2010; Medic 
and Ziman, 2010). Exposure to ultraviolet (UV) radiation is known to be linked to melanoma 
development. Following UV exposure, PAX3 is seen to be up-regulated in normal 
melanocytes, resulting in an increase in melanocyte proliferation (Dong et al., 2012; Yang et 
al., 2008). Since PAX3 is commonly expressed in melanomas (Medic et al., 2011; Medic and 
Ziman, 2010; Plummer et al., 2008; Scholl et al., 2001), this raises the possibility that PAX3 is 
involved in pathways that cause the transformation of melanocytes to malignant melanoma 
cells.  
2.1 The development of melanoma  
 
Normal skin contains neural crest derived melanocytes at the dermal-epidermal border and 
keratinocytes, the most abundant cell type in the epidermis. The number of keratinocytes is 
greater than that of melanocytes, usually in the ratio of one melanocyte for every 36 
keratinocytes. The melanocytes in naevi (a benign melanocytic lesion), and in melanomas, 
however, far outnumber the keratinocytes (Hauschild et al., 2011; Hsu et al., 2002). 
Therefore, keratinocytes, which regulate the growth of melanocytes and maintain their 
correct location in the skin, have diminished control of melanocytes in these lesions. 
Melanocytes in naevi ultimately become quiescent and proliferation ceases (Li et al., 2003). 
These melanocytes do, however, have the potential to progress to radial growth phase 
melanoma tumours. 
Melanoma can arise from naevi or occur spontaneously (de novo) (Weatherhead et al., 
2006). The transformed cells proliferate and spread in a radial manner within the epidermis, 
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known as the radial growth phase. Subsequently, if left to continue proliferating, the 
melanoma cells enter the vertical growth phase, where melanoma cells invade the dermis  
(Crowson et al., 2006). Melanoma cells have a propensity to metastasise, which involves 
their migration through the dermis, entrance into blood and lymph vessels and 
dissemination to distant sites where secondary tumours can arise (Hsu et al., 2002). 
In response to UV radiation, melanin is produced in melanocytes, a process termed 
melanogenesis. There are two types of melanin produced as a result of melanogenesis; 
eumelanin and pheomelanin. Eumelanin is a brown/black pigment and pheomelanin, a 
red/yellow pigment. Together, these pigments give the skin and hair their colour and 
protect the DNA of epidermal cells from UV radiation (Hearing, 2011).  
During the process of melanogenesis, melanin is packaged into melanosomes that travel 
along the dendritic projections of the melanocytes to the keratinocytes. One melanocyte 
may serve up to 36 keratinocytes and this is known as an epidermal-melanin unit (Figure 1). 
The melanin forms a barrier around the keratinocyte nucleus, preventing UV radiation from 
damaging the DNA of dividing keratinocytes (Hsu et al., 2002; Yamaguchi et al., 2007). 
Exposure to excessive UV radiation is known to cause an increase in melanogenesis and 
contributes to darkening of the skin, or tanning (Tadokoro et al., 2005). 
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Figure 1: The epidermal melanocyte-keratinocyte unit. Note the long dendritic projections 
of the melanocyte that transport the melanin to surrounding keratinocytes. Adapted from 
Junqueira et al (1998). 
 
2.2 Risk factors for melanoma 
 
The risk factors associated with melanoma development can be divided into two categories; 
those that are environmental and those that are genetic (Cho and Chiang, 2010; Goodall et 
al., 2008). The main environmental risk factor associated with melanoma development is UV 
radiation exposure (Leiter and Garbe, 2008; MacKie, 2006). It has been shown that multiple 
intermittent sun exposures, particularly during childhood, increase the risk of melanoma 
occurring (Veierød et al., 2003). Since PAX3 is up-regulated in melanocytes that have been 
exposed to UV radiation (Yang et al., 2008), it is possible that PAX3 has a role in the 
transformation of melanocytes into melanoma cells.  
Melanocyte 
Surrounding 
keratinocytes 
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Previous melanoma lesions, numerous benign or abnormal naevi and a family history of 
melanoma also lead to an increase in the risk of developing melanoma (Miller and Mihm, 
2006). A person’s phenotype, the colour of their hair and the number of naevi they have are 
indicators of their risk of developing melanoma. Other phenotypic traits, such as blue eyes, 
numerous freckles and red hair are also indicative of a risk of melanoma development due 
to inherited variants of the melanocortin receptor 1 (MC1R) (Miller and Mihm, 2006; 
Naysmith et al., 2004). The MC1R receptor responds to the binding of α-melanocyte-
stimulating hormone (αMSH) by initiating a signalling cascade that causes an increase in 
expression of enzymes that are crucial to melanin production (Frändberg et al., 1998). 
Inherited variants of the MC1R receptor can reduce its activity, thus increasing susceptibility 
to UV exposure and melanoma (Kennedy et al., 2001). 
People with a family history of melanoma due to inheritance of mutations in the familial 
melanoma genes cyclin-dependent kinase inhibitor 2A (CDKN2A) or cyclin-dependent kinase 
4 (CDK4), both of which are tumour suppressor genes, also have an increased risk of 
developing melanoma (Miller and Mihm, 2006). Recently, a microphthalmia-associated 
transcription factor (MITF) variant (E318K) has also been implicated in predisposition to 
melanoma (Yokoyama et al., 2011). The role of PAX3 in melanoma development has not 
been determined to date, but in this thesis we aim to further clarify its role. 
 
2.3 Treatment of melanoma 
 
According to the Australian Cancer Network Melanoma Guidelines Revision Working Party 
(2008), TNM stage 0, I and II primary stage melanomas are treated by surgical removal. 
Metastatic melanoma lesions of TNM stages III and IV, characterised by lymph node and 
distant metastases respectively, are removed by surgery as a first line treatment (Australian 
Cancer Network Melanoma Guidelines Revision Working Party, 2008). For inoperable 
melanoma, treatment involves chemotherapeutic agents or, less commonly, radiotherapy 
(Sondak et al., 2001). Until 2011, chemotherapy drugs included temozolomide (an alkylating 
agent) or decarbazine (inhibits cell replication) (Middleton et al., 2000). Interleukin-2, an 
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immunological drug that influences T-cell growth, was also used for treatment (Atkins et al., 
1999). These drugs, however, have very low success rates (less than 20%) (Agarwala, 2009).  
Emerging new treatments now target the specific mutation associated with cancer 
development, making treatment more specific and effective (Amaria et al., 2011; Becker et 
al., 2006). For example, one of the most successful new drugs for melanoma treatment 
targets a mutation in the BRAF gene, a mutation found in greater than 50% of cases (Amaria 
et al., 2011). The BRAF inhibitor Vemurafenib (Roche, Plexxikon), for example, decreases the 
activation of the MAPK pathway by inhibiting the mutant BRAF gene (V600), hence 
decreasing cell proliferation (Amaria et al., 2011; Davies et al., 2002). In general however, 
patients develop resistance to these drugs after 6-9 months (Poulikakos and Rosen, 2011). 
Recent research into the development of resistance to Vemurafenib in melanoma cells 
suggests that Stat3 and PAX3 are activated by mutant Braf (Liu et al., 2013). Further 
research suggests that the Stat3-PAX3 signalling pathway could prove an effective target for 
surmounting the resistance to Vemurafenib in melanoma (Liu et al., 2013). 
 
 
 
 
2.4 Introduction to PAX3 
 
The PAX3 gene is at the top of the hierarchy of genes that specify melanocytes. PAX genes 
are highly conserved and encode a family of transcription factor proteins having a unique 
DNA binding sequence, a 128 amino acid long paired domain (Bopp et al., 1986; Frigerio et 
al., 1986). There are nine members of the PAX gene family (PAX1-9) (Chalepakis et al., 1993) 
and these are classified into four groups according to whether they possess a full or partial 
homeodomain, a second conserved DNA binding domain and an octapeptide. PAX3 belongs 
to group III of the PAX genes, i.e. those PAX genes characterised as having both a full 
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homeodomain and an octapeptide (Lang et al., 2007; Robson et al., 2006; Walther et al., 
1991).  
The proteins encoded by the PAX genes are involved in organogenesis (Chi and Epstein, 
2002). One role of the PAX proteins is to maintain the multipotency of “stem” cells while 
they proliferate and migrate, until they terminally differentiate into lineage specific cells 
that make up several tissues. Mutations in PAX genes are known to result in the formation 
of mutant embryos with severe defects. Moreover, PAX genes are commonly expressed in 
tumours  (Balling et al., 1988; Mansouri et al., 1999). Mutations in the Pax3/PAX3 gene are 
known to produce Splotch mice and Waardenburg syndrome in humans (Baldwin et al., 
1992; Henderson et al., 1997; Pingault et al., 2010). 
The human PAX3 gene is located at 2q35 and consists of 9 exons and 9 introns, as shown in 
Figure 2A. The encoded PAX3 protein is a transcription factor that binds to specific DNA 
target sequences on downstream target genes in order to regulate their transcription. The 
PAX3 protein contains highly conserved protein domains; a paired domain, a paired-type 
homeodomain, a conserved octapeptide and a C-terminal transactivation domain rich in 
proline, serine and threonine. The paired domain and homeo-DNA binding domains are 
encoded by exons 2 to 4 and exons 5 to 6, respectively, and while they are able to bind DNA 
independently, functionally they have an interdependent relationship (Parker et al., 2004; 
Strachan and Read, 1994; Underhill and Gros, 1997). The transactivation domain, which 
interacts with RNA polymerase to activate or repress transcription, is encoded by exons 7 
and 8 (Apuzzo et al., 2004).  
The human PAX3 gene gives rise to eight different transcripts due to alternate splicing of the 
gene. These transcripts are PAX3A, PAX3B, PAX3C, PAX3D, PAX3E, PAX3G, PAX3H and PAX3I 
(also known as PAX3DQ-) (Figure 2B) (Barber et al., 1999). These mRNA transcripts produce 
proteins that differ in structure and thus function. The PAX3A and PAX3B isoforms are 
derived from exons one through four and encompass the beginning of intron 4, at which 
point the protein truncates. These two isoforms do not contain a C-terminal transactivation 
domain or a homeodomain (Tsukamoto et al., 1994). The PAX3C transcript includes exon 8 
and 5 codons of the beginning of intron 8. PAX3D does not contain intron 8, but continues 
through exons 8 and 9 (Parker et al., 2004). PAX3E includes exons 8 through 9, with the 8th 
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and 9th introns spliced out. PAX3G is a truncated isoform of PAX3D, while PAX3H is a 
truncated isoform of PAX3E, both lacking exon 8. Neither PAX3G nor PAX3H contain the 
entire transactivation domain (Parker et al., 2004). PAX3I is almost identical to PAX3D; the 
only difference is the absence of a 5' terminal glutamine at the region encoded by the intron 
exon boundary at the beginning of exon 3. As shown by the difference in exons and introns 
encoding the varied isoforms of PAX3, it can be seen that the structure of the protein differs 
primarily due to the absence of parts or the whole of the transactivation domain and as a 
result, the different isoforms have been shown to have different functions (Wang et al., 
2006).     
In fact, Wang et al. (2006) showed that the different PAX3 isoforms have different effects on 
the behaviour of transfected melanocytes. PAX3A and PAX3B have a negative effect on 
melanocyte proliferation. PAX3B also reduces melanocyte migration and increases the rate 
of melanocyte apoptosis. PAX3C and PAX3D increase cell proliferation, migration, 
differentiation and survival. PAX3E reduces melanocyte proliferation, but increases 
apoptosis. PAX3G reduces melanocyte migration and PAX3H increases melanocyte survival, 
migration and proliferation. These results show that the PAX3 isoforms have differing 
effects on melanocytes and their expression levels and roles in the development of 
melanoma remain to be identified.   
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Figure 2: The entire PAX3 gene and alternate transcripts. A) The entire PAX3 gene 
encompassing exons 1 through 9.  B) Eight alternate transcripts, of which seven are 
shown, are produced from the PAX3 gene as a result of alternate splicing. The PAX3i 
transcript is not present in the image, but contains the same sequence as PAX3d with the 
absence of a CAG encoding a glutamine (Q) at the 5' end of exon 3 (indicated by the 
arrow). The numbers are indicative of base pairs and an asterisk (*) denotes the stop 
codon. Colours are coded to indicate the sequences retained in each alternative mRNA 
transcript. The transcripts essentially run from the transcription start site (blue line) to the 
stop site (red line), contributing to their differing lengths (Medic and Ziman, 2009).  
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Activation of PAX3 
PAX3 is activated by two POU family transcription factors, BRN2 and Oct-1 (Berlin et al., 
2012). Only phosphorylated BRN2 activates PAX3 transcription, whereas PAX3 transcription 
is repressed in the absence of BRN2 phosphorylation (Pruitt et al., 2004; Zhu and Pruitt, 
2005). BRN2 also plays a role in the repression of the MITF promoter (Goodall et al., 2008). 
In this way, BRN2 regulates the migration and proliferation of cells of the melanogenic 
lineage through the activation of PAX3 by phosphorylated BRN2 and the repression of MITF 
through non-phosphorylated BRN2 (Berlin et al., 2012). BRN2 itself can be regulated by 
micro RNA, particularly miR-211. This regulation affects the potential of melanoma cells to 
invade underlying tissues (Boyle et al., 2011).  
2.5 PAX3 in melanocyte development, melanoblast maintenance and 
melanogenesis 
 
During mouse embryonic development, Pax3 is expressed in neural and neural crest cells as 
early as stage E8.5 (Figure 3) (Goulding et al., 1991). These Pax3 expressing cells arise from 
the multipotent stem cells of the neural tube, neural crest and dermomyotome and give rise 
to neural cells, skeletal muscle cells and neural crest derived lineages, including pigment 
producing melanocytes (Sommer, 2011; Yanfeng et al., 2003).  
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Figure 3: The expression of Pax3 as early as stage E8.5 in mouse neural crest cells, 
committing them to the melanogenic lineage. PAX3 remains expressed throughout the 
development of melanocytes (Medic and Ziman, 2009). 
 
The co-expression of SOX10 in a portion of the Pax3 positive neural crest cells designates 
their differentiation along the melanogenic lineage (Sommer, 2011). These neural crest cells 
then express markers indicative of melanoblasts; MITF, Kit and Dct (Hou et al., 2000; Steel et 
al., 1992), and they migrate toward the developing epidermis, where they terminally 
differentiate into melanocytes. At this stage, they express Tyr and Trp-1, which are genes 
involved in melanin production (Steel et al., 1992).  
Not all melanoblasts, however, become fully differentiated functioning melanocytes 
simultaneously. Some of the melanoblasts remain as melanoblasts within the hair follicles in 
adult skin, where they function to replace melanocytes that have been lost during the hair 
replacement cycle (Nishimura et al., 2002). The PAX3 positive melanoblasts remain at the 
base of the arrector pili muscle in the hair follicle in a quiescent state until external factors 
cause them to proliferate, differentiate and migrate to take the place of lost melanocytes in 
the epidermis (Lang et al., 2005; Nishimura et al., 2002). The PAX3 protein is required to 
maintain these melanoblasts in an undifferentiated state, while they remain committed to 
the melanocyte cell lineage (Lang et al., 2005). Furthermore, PAX3 continues to be 
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expressed in a proportion of epidermal melanocytes of adult skin, presumed to be fully 
differentiated, particularly those exposed to UV radiation (Yang et al., 2008).  
2.6 PAX3 in cell cycle inhibition and maintenance of stem cells   
 
PAX3 directs the maintenance of an undifferentiated “stem” cell-like state in melanoblasts, 
by regulation of apoptosis and cell migration. PTEN and p53 tumour suppressor genes (both 
direct targets of PAX3) are inhibited by the PAX3 protein, preventing them from activating 
factors that bring about apoptosis during the cell cycle, allowing “stem” cell survival (Furnari 
et al., 1998; Van Dyke, 2007). In addition, the BCL2L1 gene is activated by PAX3 and 
prevents apoptosis by releasing factors that inhibit apoptotic enzymes (Cheng et al., 2001). 
Neural crest derived melanoblasts are thus maintained as undifferentiated cells during 
migration to the epidermis. PAX3 regulates migration by spatial and temporal activation of 
key migration genes c-Met, NCAM, STX and TGF-β (Epstein et al., 1996; Mayanil et al., 2000; 
Nakazaki et al., 2009).  
The controversial “cancer stem cell theory” describes a population of cells within the 
tumour that, in contrast with stem cells, exhibit the ability to self-renew and propagate, in 
addition to having the potential for multidirectional differentiation, resisting apoptosis and 
having the ability to enable tumour development, growth and metastasis (Calabrese et al., 
2004; Kucia and Ratajczak, 2006; Reya et al., 2001). Recently, melanoma has been the 
subject of debate in regards to the theory of cancer stem cells (Adams and Strasser, 2008; 
Klein et al., 2007; Monzani et al., 2007; Schatton et al., 2008; Shackleton et al., 2009). 
Furthermore, as described above, PAX3 has been shown to maintain the “stem cell-like” 
state of melanocyte precursors and is also expressed in melanoma tumour cells. Thus, there 
is the potential for PAX3 to contribute to melanoma development, growth and metastasis 
through the maintenance of melanoma cancer stem cells.  
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2.7 Downstream target genes of PAX3  
 
As indicated above, PAX3 plays an important role in the development of melanocytes, 
particularly in maintenance of undifferentiated melanoblasts and is the main regulatory 
gene involved in melanogenesis. Its ability to perform its various roles is achieved by 
regulation of a variety of downstream target genes.  
 
Previous research conducted by Medic et al. (2011) showed that PAX3 differentially 
regulates downstream target genes in human epidermal melanocytes compared to 
metastatic melanoma cells (Figure 4). PAX3 has numerous downstream targets (Barber et 
al., 2002; Begum et al., 2008; Bondurand et al., 2000; Lang et al., 2005; Li et al., 2007; 
Margue et al., 2000; Nakazaki et al., 2008; Wang et al., 2007; Watanabe et al., 1998). Using a 
subset of 14 downstream target genes, based upon their association with processes likely to 
be important in melanoma progression, Medic et al. (2011) showed that the promoters of 
SOX9 and NES (involved in cell differentiation), TPD52 (cell proliferation), PTEN and TGFβ1 
(cell survival) as well as MCAM and CSPG4 (cell migration) were all bound by PAX3 in 
melanoma cells, but to a lesser extent or not at all in melanocytes (Figure 4). Furthermore, 
the expression of these genes was found to be differentially upregulated in melanoma cells 
compared to neonatal melanocytes (Figure 5) (Medic et al., 2011). This fact, together with 
the fact that PAX3 is expressed by fewer cells in normal skin, naevi and primary melanoma 
cells compared to metastatic melanoma cells (Figure 6) (Medic and Ziman, 2010), implicates 
PAX3 and genes regulated by PAX3 in melanoma. The mechanisms underpinning this 
differential regulation and expression have not been investigated prior to this research.  
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Figure 4: Differential binding by PAX3 to downstream target genes in neonatal human 
epidermal melanocytes (HEM1455) compared to metastatic melanoma cells (A2058), 
quantified by qPCR. Downstream genes involved in cell differentiation (MITF, DCT, HES1, 
SOX9 and NES), cell proliferation (CCNA2, TPD52 and NFKβ2), cell survival (BCL2L1, PTEN 
and TGFβ1) and cell migration (MCAM, CSPG4 and CXCR4) were analysed. Enrichment in 
PAX3-IP was normalised to input DNA. The fold increase over normalised IgG-IP was then 
calculated (Medic et al., 2011). 
 
 
 
Figure 5: RT-qPCR analysis of relative expression of downstream target genes of PAX3. A 
correlation was found between the binding of PAX3 to each target gene (Figure 4) and 
target gene mRNA expression levels (above) (Medic et al., 2011). 
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Figure 6: PAX3 expression in naevi, primary melanoma and metastatic melanoma relative 
to that of normal skin. The number of cells expressing PAX3 increases from melanocytes 
to melanoma cells (Medic and Ziman, 2010). 
 
2.8 Downstream targets of PAX3 differentially regulated in 
melanocytes and melanoma cells 
 
Microphthalmia associated transcription factor (MITF) 
The key downstream target of PAX3 during melanogenesis, MITF, is involved in melanocyte 
differentiation, survival and proliferation.  In normal melanocytes, the expression of MITF is 
activated by PAX3. Through binding with co-factors CREB and LEF1/β-catenin, PAX3 
enhances the transcription of the MITF gene (Figure 7) (Watanabe et al., 1998). The 
transcription factor MITF is responsible for controlling the survival, proliferation and 
differentiation of melanocytes through activation of melanocytic target genes 
(Steingrimsson, 2006). PAX3 activates the expression of MITF in early neural crest cells 
leading to the specification of melanoblasts, their migration to the epidermis and to their 
proliferation and differentiation into melanocytes. MITF activates the melanogenic cascade 
via activation of various downstream targets, including Tyr, Trp-1 and Dct, enzymes 
responsible for the final steps of melanogenesis, as well as MelanA and gp100/Silv, which 
are structural components of melanosomes (Figure 7) (Yasumoto et al., 1997). 
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PAX3 binds the MITF promoter in melanocytes and melanoma cells, however in melanoma 
the tight regulation of MITF by PAX3 is lost and MITF is not regulated by PAX3 alone. In 
melanoma cells, MITF activation is also by Wnt3a signalling, which causes β-catenin and Lef1 
transcription factors to bind to the promoter region of the MITF gene, allowing transcription 
to occur (Cook et al., 2005; Takeda et al., 2000b).  This alteration in MITF regulation allows 
activation of proliferation pathways in melanoma cells (Cronin et al., 2009). 
 
 
Figure 7: The role of Pax3 in melanogenesis. Pax3 activates MITF, which in turn activates 
Silv, Tyr, Melan-A and Trp-1. Pax3 and MITF compete for the promoter of Dct (Medic and 
Ziman, 2009).  
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Dopachrome tautomerase (DCT) 
Dct is involved in differentiation of melanoblasts. During development PAX3 inhibits the 
expression of Dct, allowing the melanoblasts to remain in their undifferentiated cell state 
(Lang et al., 2005), allowing cells to proliferate, migrate and survive.  
The Dct enzyme acts together with tyrosinase and Trp-1 during melanogenesis. Dct causes 
dopachrome to be converted to dehydroxyindole-2-carboxylic acid (DHICA)(Figure 8), which 
is a precursor of the pigment, eumelanin (Park et al., 2009). Dct is activated by MITF, but 
MITF competes with PAX3 to bind to the Dct promoter. In fact, PAX3 has a stronger affinity 
for the Dct promoter than MITF (Lang et al., 2005). The displacement of PAX3 by β-catenin, 
which is regulated by the Wnt signalling pathway, allows MITF to bind freely to the Dct 
promoter, resulting in Dct activation (Figure 9). The inhibition of Dct by PAX3 is important 
for the maintenance of melanoblasts during their proliferation and migration to the 
epidermis and the hair follicle. Without this inhibition, melanoblasts differentiate into 
melanocytes (Lang et al., 2005).  
 
As indicated by Figure 4, DCT is bound by PAX3 in melanoma cells as well and while PAX3 
up-regulation leads to DCT gene inhibition and maintenance of a stem cell state in 
melanoblasts, this regulation in melanoma cells (Medic et al., 2011) remains to be 
determined. 
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Figure 8: The genes involved in melanogenesis. Note that PAX3 is the key regulatory gene 
for this process; without PAX3 the entire melanogenic cascade is not activated (Melanoma 
Molecular Map Project, 2011). Also note that in this image Dct is referred to as TRP2. 
 
 
 
 
 
a b 
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Figure 9: The interaction between Pax3, Dct and Wnt. Pax3 inhibits the Dct gene (a), 
whereas Wnt causes the inhibition of Pax3 through β-catenin, which displaces Pax3 and 
allows Dct transcription (b). Adapted from Lang et al. (2005). 
 
 
Hairy and enhancer of split-1 (HES1) 
HES1 is a basic helix-loop-helix (bHLH) gene encoding a transcription factor repressor 
(Kageyama et al., 2000). The primary role of HES1 is to inhibit apoptosis in melanoblasts, 
thereby playing a critical role in the survival of these melanocyte precursors (Moriyama et 
al., 2006). Additionally, HES1 is expressed in melanoma cells and has been shown to repress 
promoter activity of MAP2, a microtubule-associated protein, during melanoma 
progression, leading to cell survival (Bhat et al., 2006; Soltani et al., 2005). 
SRY (Sex-determining region Y) box 9 (SOX9) 
The SOX9 gene belongs to the SOX family of transcription factors. The SOX9 protein is 
essential in development, aiding in sex determination and cartilage development (Nakazaki 
et al., 2008). More importantly, SOX9 plays a role in the differentiation of melanoblasts into 
melanocytes and the production of melanin during melanogenesis (Cook et al., 2005). 
Furthermore, SOX9 transcription is regulated by PAX3 (Figure 4) and is upregulated after 
exposure to UV radiation by PAX3 (Passeron et al., 2007). SOX9 is bound by PAX3 in 
melanoma cells at a significantly higher rate than in melanocyte cells, so it is speculated that 
the regulation of SOX9 by PAX3 in melanoma cells may lead to their stem-like phenotype, 
particularly of the more metastatic phenotype (Medic et al., 2011).  
 
Nestin (NES) 
NES is an intermediate filament expressed predominantly in stem cells of neuroepethelial 
lineage. It has been shown to be expressed in stem cells that reside in hair follicles until 
these cells mature and NES expression ceases (Amoh et al., 2005). A study conducted by 
Ehrmann et al (2005) revealed that malignant melanoma tumours are positive for NES, 
whereas benign naevi were NES negative. Its importance here lies in the fact that the 
protein is highly expressed in proliferating progenitor and stem cells of neuroectodermal 
origin (Brychtova et al., 2006; Redies et al., 1991). The protein ceases to be produced when 
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these cells mature, however, it is re-expressed in tumour cells of neuroectodermal (such as 
melanoma) and mesenchymal lineage (Ehrmann et al., 2005); and in melanoma it is 
presumably regulated by PAX3 (Medic et al., 2011). 
Cyclin A2 (CCNA2) 
CCNA2 is a cell cycle regulator, required to allow cells to progress from the S phase to the M 
phase of the cell cycle (Flørenes et al., 2001; Pagano et al., 1992). In normal melanocytes, 
CCNA2 is upregulated after transfection with PAX3 (Wang et al., 2007). Previous research of 
PAX3 and its downstream targets demonstrated a low enrichment of the promoter of 
CCNA2 in melanocytes, signifying that PAX3 has the potential to regulate melanocyte 
proliferation through activation of CCNA2 (Medic et al., 2011).    
The binding of PAX3 to the CCNA2 promoter has been shown to occur to a larger extent in 
melanoma cells compared to melanocytes (Medic et al., 2011). Furthermore, knockdown of 
PAX3 in melanoma cells inhibits cell proliferation and arrests the cell cycle in both the S and 
G2/M phases (He et al., 2010). This shows that activation of CCNA2 by PAX3 presumably 
contributes to proliferation of both melanocytes and melanoma cells. 
Tumour protein D52 (TPD52) 
TPD52 is involved in cell proliferation, exerting its effects on the cell cycle at the G2/M 
transition phase (Boutros et al., 2004). TPD52 does not show enrichment when analysed by 
PAX3-IP in melanocytes, however, it does so in melanoma cells (Figure 4), which suggests 
that PAX3 regulates different pathways of proliferation in these two cell types (Medic et al., 
2011). Furthermore, TPD52 overexpression is associated with cell proliferation in cancer, 
including in melanoma (Roesch et al., 2007) and the ability of PAX3 to regulate proliferation 
of melanoma cells might be through the activation of TPD52. 
BCL2-like protein (BCL2L1) 
The BCL2L1 gene regulates anti-apoptosis/cell survival during development when cells are 
undergoing proliferation (Margue et al., 2000). PAX3 activates the BCL2L1 gene directly in 
melanoma cells (Strasser and Youle, 2008) but not in melanocytes (Medic et al., 2011), 
presumably reducing apoptosis and increasing cell survival (Margue et al., 2000). 
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Furthermore, it has been suggested that PAX3 and BCL2L1 are part of the same pathway 
that inhibits apoptosis - the viability of rhabdomyosarcoma cells decreased to a similar 
extent when treated with antisense oligonucleotides for PAX3 or BCL2L1 or a combination 
of both (Margue et al., 2000). 
Phosphatase and tensin homolog (PTEN) 
The PTEN gene is a tumour suppressor gene which is responsible for controlling the 
progression of the cell cycle by acting on the G1 phase checkpoint. Through p27Kip1, a cell 
cycle inhibitor, PTEN antagonistically regulates the PI3K/AKT signalling pathway (Li and Sun, 
1998; Zhou et al., 2003). It is responsible for binding to PIP3 and deactivating it via 
dephosphorylation. If PIP3 is not dephosphorylated it can cause the expression of its 
downstream target gene Akt, which is responsible for proliferation of cells, anti-apoptosis 
and the formation of tumours (Inoue-Narita et al., 2008). Down-regulation of PTEN sees an 
increase in activation of Akt, which increases phosphorylation of targets involved in 
regulating apoptosis (Cantley and Neel, 1999).  
The PTEN protein also prevents growth, migration and invasion of cells via the Shc adaptor 
protein and PDGF (Gu et al., 1999). In primary melanoma, less than 15% of cases have a 
mutation in the PTEN gene and the loss of a PTEN allele at one locus (loss of heterozygosity) 
is shown in 30% to 50% of cases (Reifenberger et al., 1999). However, up to 91% of 
metastatic melanoma cases show a decrease or complete absence of PTEN protein 
expression (Whiteman et al., 2002). PTEN is bound by PAX3 in melanoma cells, but not in 
melanocytes (Figure 4, Medic and Ziman, 2011) and may be down-regulated by PAX3 in 
melanoma cells, resulting in a decrease in its function of PIP3 dephosphorylation and 
therefore a decrease in tumour suppressor function (Li et al., 2007; Medic et al., 2011). 
Essentially, if PAX3 levels rise, PTEN levels decrease and so does its apoptotic role (Li et al., 
2007). 
Transforming growth factor beta (TGF-β) 
TGF-β is directly regulated by PAX3, but in turn represses PAX3 transcription in a feedback 
loop (Yang et al., 2008). TGF-β plays a crucial role in cell-cell adhesion and migration by 
regulating genes responsible for modifying the cytoskeleton or adhesion molecules and 
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their receptors (Mayanil et al., 2006). TGF-β regulates these cellular properties by activating 
Wnt inhibitors, that bring about the alteration of the cytoskeleton and activation of cell 
adhesion molecules, increasing the metastatic potential of cells (Yang et al., 2008). 
Additionally, neural tube defects are apparent in TGF-β knock-out and Pax3-deficient 
Splotch mice, demonstrating that TGF-β is regulated by Pax3 and plays a role in the 
migration of precursor cells during development (Sanford et al., 1997). The TGF-β promoter 
is bound by PAX3 in melanoma cells to a greater extent than in melanocytes and the 
expression of TGF-β is also significantly higher in melanoma cells compared to melanocytes 
(Figures 4 and 5, Medic et al., 2011). The implication of an increase in TGF-β is that it could 
possibly contribute to melanoma cell migration and metastasis (Hoek et al., 2006; Medic et 
al., 2011; Yang et al., 2008). 
 Melanoma cell adhesion molecule (MCAM) 
MCAM is a transmembrane glycoprotein and is a key factor in progression of melanoma 
from the radial growth phase to vertical growth phase (Johnson, 1999; Lehmann et al., 
1987; Mills et al., 2002). The MCAM gene encodes a protein involved in cell migration (Xie et 
al., 1997). In general, MCAM is not expressed in normal adult epidermal melanocytes, but it 
is expressed in melanoblasts of the hair follicle, where it presumably regulates migration to 
the epidermis. Moreover, MCAM is directly regulated by PAX3 in melanoma cells to a 
significantly higher extent than in melanocytes (Medic et al., 2011). MCAM plays a key role 
in melanoma cell migration and adherence to endothelial cells, which also express MCAM 
(Figure 10). The activation of MCAM by PAX3 in melanoma cells is thought to play a role in 
melanoma cell migration and metastasis (Moh and Shen, 2009; Yoshioka et al., 2003). 
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Figure 10: The interaction between keratinocytes and melanocytes (a) and keratinocytes 
and melanoma cells (b). The melanocytes are kept in place due to the attachment to 
keratinocytes via cadherin molecules. When the melanocytes transform and proliferate, 
they no longer attach to keratinocytes. Instead, they attach to each other through MCAM 
molecules. Adapted from Li et al (2003).  
 
Chondroitin sulfate proteoglycan 4 (CSPG4) 
The CSPG4 protein is a cell surface proteoglycan that has little to no expression in normal 
epidermal melanocytes, but has been associated with melanoma (Campoli et al., 2004). 
Increased levels of the proteoglycan CSPG4 have been found in benign and dysplastic naevi 
and in both primary and metastatic melanomas (Campoli et al., 2004). CSPG4 contributes to 
the adhesion, motility and invasion of tumour cells (Yang et al., 2009). PAX3 binding to 
CSPG4 is significantly increased in melanoma cells compared to melanocytes, and its mRNA 
levels are significantly increased in melanoma cells (Figures 4 and 5), suggesting that PAX3 
may regulate CSPG4, contributing to melanoma cell migration and metastasis (Medic et al., 
2011). 
Chemokine (C-X-C motif) receptor 4 (CXCR4) 
Melanoma cells 
crossing the basement 
membrane 
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CXCR4 is a chemokine receptor that elicits cell migration (Robledo et al., 2001; Rollins, 
1997). CXCR4 and its ligand, CXCL12, have been implicated in the migration and positioning 
of melanoblasts as well as in the metastatic progress of numerous neoplasms, including 
melanoma (Belmadani et al., 2009; Murphy, 2001; Robledo et al., 2001). Research 
conducted by Scala et al. (2005) showed a correlation between CXCR4 expression and 
unfavourable prognosis in patients with malignant melanoma. PAX3 binds to CXCR4 in 
melanoma cells and melanocytes, and there is an increase in CXCR4 mRNA expression in 
melanoma cells compared to melanocytes (Figures 4 and 5) (Medic et al., 2011). This 
suggests that PAX3 regulation of CXCR4 may result in melanoma cell migration and 
metastasis. 
All of the aforementioned genes have a role in the proliferation, migration, survival, 
differentiation or melanogenic functions of either melanocytes or melanoma cells, or both, 
and are all regulated by PAX3, either by inhibition or activation. Several of these genes are 
differentially regulated in melanoma cells compared to melanocytes. The mechanism by 
which this differential regulation takes place is presumably due to an alteration in the PAX3 
gene or protein which affects the activation of its downstream targets. Such changes could 
include variation in PAX3 isoform profiles leading to activation or inhibition of different 
downstream target genes. Moreover, isoforms may have altered post-translational 
modifications, again altering binding to downstream target genes, potentially resulting in 
abnormal pathway activation in the cell. 
2.9 Post-translational modifications of PAX3  
 
Not only can genes be regulated by alternative splicing, but the proteins produced can also 
be modified and controlled through post-translational modifications. Three protein 
modifications that commonly occur in cells to regulate protein function are 
phosphorylation, acetylation and ubiquitination. These modifications are formed by the 
attachment of an organic group to specific amino acid residues, altering the three 
dimensional structure and thus the function of the protein. 
Phosphorylation of the PAX3 protein, as shown in myogenic cells, results in attachment of a 
phosphate moiety to serine residues 201, 205 or 209 (Dietz et al., 2011; Miller et al., 2008). 
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Research conducted by Miller and Hollenbach (2007) on mouse primary myoblasts showed 
that in the first 24 hours of embryonic muscle cell differentiation the levels of Pax3 protein 
decreased, whereas the levels of Pax3 mRNA did not. Labelling with [32P]-orthophosphate 
demonstrated that the Pax3 protein was phosphorylated in vivo at serine residues 201, 205 
and 209 (Miller et al., 2008). Moreover, the changing pattern of phosphorylation of the 
protein at these sites, resulted in the switching of proliferating myoblasts to differentiating 
myoblasts (Dietz et al., 2011). 
Ichi et al. (2011) showed that the PAX3 protein can be acetylated at lysine (K) residues 437 
and 475, and this dramatically affects neural development. Acetylated PAX3 upregulates 
Neurog2 expression, resulting in differentiation of neuroblasts into neural cells. Moreover, 
acetylated PAX3 downregulates Hes1, thus inhibiting proliferation of these cells (Figure 11). 
When PAX3 is deacetylated by SIRT1 (a deacetylase enzyme), there is an up-regulation of 
Hes1 and down-regulation of Neurog2, resulting in proliferation of undifferentiated cells. 
This shows that acetylation of the PAX3 protein can alter the regulation of downstream 
target genes and ultimately cell fate, switching cells from undifferentiated to differentiated 
cells (Ichi et al., 2011).  
 
 
Deacetylated  
Pax3 
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Figure 11: Acetylation of PAX3 promotes neurogenesis through the activation of Neurog2, 
while deacetylation of PAX3 by SIRT1 promotes stem cell proliferation and maintenance 
through the activation of Hes1. Adapted from Ichi et al. (2011). 
 
Ubiquitination, the process by which a ubiquitin moiety is attached to a protein, causes it to 
have an altered function or be recognised by proteases and degraded. Ubiquitination at 
lysine residues involves attachment of a 76 amino acid ubiquitin molecule through the 
action of ubiquitin-activating enzyme (E1), cysteine enzyme (E2) and ubiquitin ligase (E3) 
(Figure 12) (Kaiser and Huang, 2005). Boutet et al. (2010; 2007) have shown that 
monoubiquitination occurs at the PAX3 protein during skeletal muscle development and this 
causes the PAX3 protein to be degraded by proteases. This degradation of PAX3 inhibits the 
protein from activating pathways that maintain undifferentiated myoblasts, thus allowing 
skeletal muscle cell differentiation.  
 
Figure 12: The process of ubiquitination: Enzymes attach ubiquitin moieties to proteins to 
mark them for degradation by proteases. Adapted from Boutet et al (2010; 2007). 
 
Summary: 
In this project we aimed to assess whether PAX3/PAX3 is differentially expressed and 
differentially modified post-translationally in human melanocyte cells and melanoma cell 
lines as this may affect its regulation of downstream target genes and possibly play a role in 
driving pathways that lead to transformation of cells.  
Lysine residue 
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3. Theoretical Framework 
 
PAX3 is expressed in embryonic melanoblasts, melanoblasts in the hair follicle niche, adult 
melanocytes (epidermal and follicular) and in naevi and melanoma cells. It is responsible for 
regulating pathways involved in cell survival, differentiation, migration and proliferation. 
The exposure to UV radiation up-regulates the expression of PAX3 in epidermal 
melanocytes. This upregulation of PAX3 results in cells that can survive, proliferate and 
migrate. While these are characteristics of developing cells, they are also highly applicable 
to cancer cells. PAX3 has been shown to differentially regulate downstream target genes in 
melanoma cells compared to melanocytes. This gives us reason to believe that PAX3 is 
involved in pathways that lead to melanoma progression and therefore further investigation 
is required to examine whether any alterations in the PAX3 gene, its transcript expression 
profile or protein modifications lead to alternate roles in melanoma cells compared to 
melanocytes, via differential regulation of downstream target genes.  
The exact role of PAX3 in adult melanocytes and melanoma cells is not clear. It has been 
confirmed that PAX3 has an anti-apoptotic function in melanoma cells and it maintains an 
undifferentiated state in melanoblasts, but these might not be the only roles it plays in 
epidermal melanocytes and melanoma cells. The purpose of this investigation is to 
determine whether there are any differences between melanocytes and melanoma cells in 
the PAX3 gene, its splice variants, its encoded protein isoforms or its downstream targets. 
Differences in PAX3 transcripts or proteins between melanocytes and melanoma cells could 
be harnessed to provide strategies for therapeutic intervention. 
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4. Hypotheses 
 
Previous research has shown PAX3 to differentially regulate downstream target genes in 
melanocytes and metastatic melanoma cells. We hypothesised that the differential 
regulation of downstream targets could be due to differential expression of PAX3 alternate 
transcripts, or differences in post-translational modifications of the PAX3 protein between 
melanocytes and melanoma cells. Therefore, PAX3 alternate transcript expression profiles 
and the presence of post-translational modifications, particularly acetylation, 
phosphorylation and ubiquitination, were investigated in normal human epidermal 
melanocytes and primary and metastatic melanoma cells. Furthermore, using PAX3 silencing 
experiments, differential regulation of downstream target genes was confirmed in primary 
melanoma cells compared to normal melanocytes and metastatic melanoma cells.  
5. Aims 
 
The aims of this research were: 
1. To confirm PAX3 expression and compare levels of mRNA and protein between 
neonatal and adult melanocytes and primary and metastatic melanoma cells. 
2. To compare PAX3 transcript expression profiles between neonatal and adult 
melanocytes and primary and metastatic melanoma cells. 
3. To compare post-translational modifications of PAX3 including phosphorylation, 
acetylation and ubiquitination, between neonatal and adult melanocytes and 
primary and metastatic melanoma cells. 
4. To confirm that previously identified downstream target genes are differentially 
regulated in neonatal and adult melanocytes relative to melanoma cells lines after 
PAX3 silencing in vitro. 
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6. Methods and Materials 
6.1 Summary  
 
PAX3 expression was analysed in four groups of cell types - neonatal and adult normal 
human epidermal melanocytes and primary and metastatic melanoma cell lines. Six primary 
and five metastatic melanoma cell lines were analysed for PAX3 expression to confirm a 
similar expression pattern within groups of cell lines. Thereafter, one cell line from each of 
the primary and metastatic groups, in addition to neonatal and adult melanocytes, was used 
for further analysis throughout the remainder of this research. Cells were stained using 
immunocytochemical methods to confirm PAX3 expression. Furthermore, total RNA and 
total nuclear proteins were extracted from the cells and levels of PAX3/PAX3 expression 
were analysed by real time RT-qPCR and western blot, respectively. To assess PAX3 
alternate transcript expression profiles in these four cell types, RNAseq was used. To test for 
post-translational modifications of the PAX3 isoforms in the four cell types, 
immunoprecipitation and western blot were performed. PAX3 silencing was used to confirm 
that PAX3 does in fact differentially regulate downstream targets in the four cell types. The 
outcomes of these experiments confirm a differential role of PAX3 in melanocytes and 
melanoma cells. 
Ethics was granted by the Human Research Ethics Committee at Edith Cowan University 
(project number 8375).  
6.2 Cell cultures 
 
Human melanoma and melanocyte cell cultures were maintained as a monolayer at 37˚C, in 
5% CO2. Metastatic melanoma cell lines (A2058, M14, SKMEL2, SKMEL5 and UACC62) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal 
bovine serum (FBS) (Sigma Aldrich), L-glutamine (300µg/ml), penicillin (400 U/ml) and 
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streptomycin (50µg/ml). Primary melanoma cell lines (MM200, MM229, MM329, MM540 
and MM622) were maintained in RPMI-1640 media supplemented with 10% FBS and 1% 
antibiotics (penicillin and streptomycin), whereas WM115 primary cell line was cultured in 
Eagle’s minimum essentials media (EMEM) supplemented with 10% FBS and 1% antibiotics 
(penicillin and streptomycin). One representative cell line from the group of primary and 
metastatic cell lines was chosen for further investigation. Adult human epidermal 
melanocyte primary culture (NHEM-a (P), PromoCell) was maintained in Melanocyte Growth 
Media (PromoCell) and adult melanocyte primary culture (NHEM-a (I), Invitrogen) was 
maintained in 254 media (Invitrogen). Neonatal human epidermal melanocyte primary 
culture (NHEM-n, Promocell) was maintained in Melanocyte Growth Media (PromoCell). 
The media was replaced every 48 hours until cells became 80-90% confluent. Cells at 
confluency were detached with trypsin/EDTA (Invitrogen). An equal volume of Trypsin 
Neutralising Solution (Invitrogen) was added to melanocyte cultures. Trypsin/EDTA used in 
melanoma cell line cultures was neutralised using respective media supplemented with FBS. 
The cells were then transferred to a falcon tube and centrifuged at 180xg for 7 minutes (for 
melanocytes) or 300xg for 5 minutes (for melanoma cells). The supernatant was discarded, 
new medium was added and cells were resuspended before being replated. Seeding density 
for melanocytes was 8.6 x 103 cells/cm2, and for melanoma cells was 2.8 x 103 cells/cm2.  
6.3 RNA extraction 
 
Total RNA was extracted from the cultured cells using the Isolate RNA mini Kit (Bioline) 
according to the manufacturer’s instructions. Briefly, cells grown to 80% confluency were 
washed with PBS and detached from the flask with trypsin/EDTA. Up to 5x106 cells were 
transferred into a fresh 10ml centrifuge tube and pelleted by centrifugation at 300xg for 5 
minutes (melanoma cells) or 180xg for 7 minutes (melanocytes).  450μl Lysis Solution was 
added to cells and mixed thoroughly. Homogenised lysate was placed into a shredding 
column which was centrifuged for 2 minutes at 12000rpm. Thereafter, 450μl of 70% ethanol 
was added to the flowthrough and the solution was transferred to a spin column and 
centrifuged at 12000rpm for 2 minutes. Following two washing steps, the RNA was eluted 
from the column in 40μl of RNase-free water and stored at -80⁰C until analysed further. 
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The integrity of the RNA was assessed using a Bioanalyser (Agilent 2100). An aliquot of 
filtered gel was prepared as per the manufacturer’s instructions. Using the chip priming 
station, the gel was loaded onto the chip. 1μL of dye was added to the 12 sample wells and 
the ladder well. 1μL of each RNA sample and the ladder were loaded into their respective 
wells and the chip was vortexed for 1 minute. The chip was then subject to electrophoresis 
and the fluorescence assessed, from which the concentration of RNA was provided in ng/μL, 
as was the RNA integrity number (RIN) out of 10, showing the quality of the RNA. Only RNA 
with a RIN value above 7 was used.   
6.4 Reverse transcription and qPCR 
 
To determine the level of PAX3 mRNA and its downstream targets in all cell lines, RNA was 
isolated and reverse transcribed from each cell line and subjected to real time qPCR using an 
iQ5 cycler (Bio-Rad). To do this, total RNA was reverse transcribed using the Omniscript RT 
kit (Qiagen), according to the instructions. Briefly, 500ng of total RNA (or 200ng for silencing 
experiments) was reverse transcribed in a 20μl reaction mixture containing: 1x RT Buffer, 
0.5mM dNTP, 1μM Oligo-dT primer (Qiagen), 0.5 units/μL of RNase OUT Recombinant 
Ribonuclease Inhibitor, RNase-free water and RNA sample. The reaction was incubated for 1 
hour at 37⁰C, followed by 5 minutes at 95⁰C and finally cooled to 4⁰C. 
qPCR 
1μl of template cDNA, 0.2μM primers and KAPA SYBR FAST qPCR Master Mix 
(KapaBiosystems) was used in a final reaction volume of 15μl. Primers used were as follows: 
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Table 1: Primers used in RT-qPCR analysis (Medic et al., 2011). 
Gene  Forward primer Reverse primer 
GAPDH 5'-TTCTTTTGCGTCGCCAGCCGAG-3' 5'-GTGACCAGGCGCCCAATACGA-3' 
PAX3 5'-AGCCGCATCCTGAGAAGTAA-3' 5'-CTTCATCTGATTGGGGTGCT-3' 
MITF  5'-CGTCTCTCACTGGATTGGTG-3' 5'-CCGTTGGGCTTGCTGTATGT-3' 
DCT   5'-CGACTCTGATTAGTCGGAACTCA-3' 5'-GGTGGTTGTAGTCATCCAAGC-3' 
HES1 5'-AGAAAGATAGCTCGCGGCATTCCA-3' 5'-TTCCCCAGCACACTTGGGTCT-3' 
SOX9 5'-AGCAAGACGCTGGGCAAGCTCTGG-3' 5'-CCCGTTCTTCACCGACTTCCTCCG-3' 
NES 5'-GCGCACCTCAAGATGTCCCTCA-3' 5'-GGTGTTTGCAGCCGGGAGTTC-3' 
CCNA2 5'-AGAGGCCGAAGACGAGACGG-3' 5'-TGAATGGTGAACGCAGGCTGTT-3' 
TPD52 5'-ACATGGACCGCGGCGAGCAA-3' 5'-GTGGCACTGATCGTGGCAGCAAC-3' 
BCL2L1 5'-CAGGTATTGGTGAGTCGGATCGC-3' 5'-GGCTCTCGGCTGCTGCATTGTT-3' 
PTEN 5'-GCTGGAAAGGGACGAACTGGTGTA-3' 5'-CACATAGCGCCTCTGACTGGGAA-3' 
TGFβ1 5'-GTCACCGGAGTTGTGCGGCA-3' 5'-GCAGTGGGCGCTAAGGCGAA-3' 
MCAM 5'-GGGTACCCCATTCCTCAAGT-3' 5'-CTGGGACGACTGAATGTGG-3' 
CSPG4 5'-GCCTTCACTGTCACTGTCCTGCCT-3' 5'-TCCTCAGACCCAGAGTCGCCGT-3' 
CXCR4 5'-GCCTTCACTGTCACTGTCCTGCCT-3' 5'-AGTCCCCTGAGCCCATTTCCTCG-3' 
 
Binding sites of the PAX3 forward and reverse primers, as well as the expected length of the 
product, for each of the PAX3 transcripts are detailed in Figure 13. 
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Figure 13: Binding sites for the PAX3 forward and reverse primers on each of the 
PAX3 transcripts. The expected product size was 148bp. The reverse PAX3 primer 
does not align to PAX3A or PAX3B. 
 
Amplification was performed as follows: Briefly, samples were amplified with a pre-cycling 
hold at 95˚C for 3 seconds, followed by 40 cycles of a 2-step protocol (denaturation at 95˚C 
for 3 seconds, followed by annealing at 60˚C for 30 seconds). Data acquisition was 
performed at the annealing step of each cycle. Melt curve analysis to determine reaction 
specificity was included in the protocol with the following additional steps; 1 minute at 95⁰C, 
1 minute at 55⁰C followed by 81 cycles with the temperature increasing from 55 by 0.5⁰C per 
cycle and data collected every 30 seconds. Products were initially analysed by 2% agarose-
gel electrophoresis and ethidium bromide staining to confirm the production of a single 
amplicon of the correct size. 
Each sample reaction was performed in triplicate, as biological replicates and included 
reagent controls (reagents without RNA or cDNA) and each Ct value was generated from a 
standard curve that was produced initially to confirm that each reaction had the same 
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efficiency. Reaction efficiency of between 90 and 100% and a correlation coefficient of over 
0.99 was considered appropriate for each reaction. The threshold cycle value of the sample 
was determined from the standard curve. The mean Ct value of the triplicate for each 
sample reaction was used to calculate fold change over GAPDH (ΔCt).  
Statistical analysis: Statistical analysis of changes in gene expression in the different cell 
lines was performed using a Kruskall-Wallis test. A Kruskall-Wallis test was performed as 
these data sets did not exhibit a normal distribution. The house-keeping gene, GAPDH was 
used to calculate the fold changes of expression levels. Each gene expression analysis was 
performed in triplicate and a mean was taken from these values. A Kruskall-Wallis test was 
used to compare the expression of each gene relative to that of GAPDH.  
6.5 RNAseq 
 
To assess PAX3 alternate transcript expression profiles, next-generation sequencing for 
transcriptome analysis (or RNAseq) was used. Briefly, total RNA was extracted from all of 
the representative cell types as previously described (Section 6.3). Library construction and 
100bp paired-end sequencing were performed by the Australian Genome Research Facility 
(AGRF) Services on Illumina HiSeq2000 systems using 1-10µg of total RNA per sample. 
Custom data alignment to the known PAX3 sequences was performed and analysed for 
alternative transcript identification.  
The Illumina HiSeq2000 method (Figure 14) reads up to 100 base pairs per read. Using the 
paired-end method enables the mRNA strand to be read from both directions, with 100 
base pair reads from each end giving a reading of 200 base pairs from each strand resulting 
in the formation of short fragments of sequenced material. The short read fragments were 
then compiled together to form a library. These sequences were then compared to 
reference sequences for PAX3 transcripts. Any alternative splicing was identified by 
analysing the junction reads of the sequences. RNAseq also allows the expression of each 
transcript to be quantified by calculating the amount of junction reads that correspond to 
exons of the reference sequence. Thus a data set of PAX3 expression profiles for each 
alternate transcript, for each cell type, was constructed. 
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The sequence reads generated were cleaned and aligned against the human genome using 
the Tophat aligner. Raw gene counts that were mapped to known gene sequences in the 
human genome were used to calculate differential gene expression in the samples. The 
Cufflinks tool was used to assemble the transcripts and to check for novel transcript 
expression. Cuffmerge and cuffdiff were then used to first merge the compared samples and 
then analyse differential expression. Expression levels were then calculated as number of 
reads per kilobase of exon model per million mapped fragments. 
 
 
Figure 14: Illumina HiSeq 2000 protocol. Adapted from Gerstein et al. (2009). 
 
6.6 Immunocytochemistry 
 
First, to confirm PAX3 protein expression in the cell lines, immunocytochemistry was 
performed as previously described (Medic and Ziman, 2010, 2011). Briefly, 5x104 cells per 
cover slip were grown for 24 hours. Cells were fixed in 4% paraformaldehyde and 
permeabilised for 15 minutes at room temperature with PBS containing 0.2% Triton-X100 
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(0.2% PBST), then blocked with 10% normal goat serum (NGS) in 0.2% PBST for 1 hour. Cells 
were stained overnight at 4˚C with mouse monoclonal PAX3 antibody (DSHB) at 1:50 
dilution. Excess primary antibody was washed off by rinsing in PBS three times for 5 
minutes. This was followed by incubation with anti-mouse IgG conjugated with Dylight-550 
for 1 hour. All antibodies were diluted in 0.2% PBST containing 1% NGS. Cover slips were 
mounted onto microscope slides with Prolong Gold Antifade Reagent with DAPI (Invitrogen) 
in order to stain cell nuclei.  Slides were viewed with an Olympus BX41 epi-fluorescent 
microscope. Controls with primary antibodies withheld were also included to ensure non-
specific staining was not evident.  
6.7 Western blot 
 
To assess the level of expression of PAX3 proteins in the melanoma cell lines and primary 
melanocytes, western blot was performed as previously described (Medic et al., 2011). To 
extract total cellular proteins from cultured melanoma and melanocyte cells, cells were 
washed twice with ice-cold PBS and then scraped from the base of the flask into a solution 
of PBS containing protease inhibitor cocktail (PIC, 1x, Roche). Cells were transferred into 
individual falcon tubes and centrifuged at 300xg for 5 minutes. Cells were resuspended in 
300µl cell lysis buffer (50mM pipes, 85mM KCl, 1% Nonidet P-40, 1x PIC, pH 8.0), briefly 
vortexed and incubated on ice for 30 minutes. Cell debris was centrifuged at 10000rpm for 5 
minutes at 4˚C and the supernatant (containing cytosolic proteins) was collected and stored 
at -80˚C to later analyse by SDS-PAGE alongside the total nuclear protein in order to confirm 
the protein extraction procedure was effective in isolating the nuclear proteins of the cells. 
The cell pellet was then resuspended in 150µL of nuclear lysis buffer (50mM Tris, 10mM 
EDTA, 1% SDS, 1x PIC, pH 8.0), vortexed and incubated on ice for 30 minutes. The samples 
were then passed through a 27 gauge needle to aid lysis. The samples were centrifuged at 
12000rpm for 10 minutes at 4˚C. The supernatant (containing nuclear proteins) was 
transferred to a new tube and stored at -80˚C for further analysis. The pellet (containing 
DNA) was discarded.  
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The concentrations of extracted proteins were determined using the bicinchoninic acid 
(BCA) protein assay kit (Pierce) and absorbance was read using the Fluostar Optima plate 
reader. 
Cell lysates were diluted to a standard of 20µg (10µg for silencing experiments) with TBS. 
Sample reducing agent (4x) and sample buffer (10x) were added to each sample, vortexed 
and heated at 70˚C for 10 minutes. The electrophoresis tank was filled with 1x NuPAGE MES 
SDS running buffer. Protein samples were loaded onto a NuPAGE Bis-Tris precast 10 well gel 
(Life Technologies) alongside 7µL Novex Sharp pre-stained protein standard (Life 
Technologies) and the gel was run at constant 400A for 2 hours.  
Proteins were transferred from the gel onto nitrocellulose membrane (Biorad) as follows: A 
transfer sandwich was assembled under transfer buffer (0.02M Tris, 0.08M Glycine, 0.001M 
SDS, 20% methanol). The sandwich was placed into the plastic transfer cassette and then 
into the transfer tank. The internal and external sections were filled with transfer buffer and 
run at a constant 0.25A overnight at 4°C. After disassembly, the nitrocellulose membrane 
was cut for orientation of protein samples and the ladder marked on the membrane.  
The Westernbreeze chemiluminescent detection kit (Life Technologies) was used for 
immunodetection of the proteins by western blot as per the instructions. The nitrocellulose 
membrane was immersed in blocking buffer (Life Technologies) for 30 minutes. The anti-
PAX3 antibody (mouse monoclonal, DSHB) at working concentration 1:1000 (diluted in 
blocking buffer) was added to the nitrocellulose membrane and incubated overnight at 4˚C. 
The membrane was washed 4 times at room temperature using the wash buffer provided in 
the kit for 5 minutes on a rocking platform. Secondary IgG antibody linked to alkaline 
phosphatase, at a working concentration 1:2000, was applied to the nitrocellulose 
membrane and incubated for 30 minutes at room temperature on a rocking platform. The 
membrane was then washed 4 times, as previously described.  
For the immunoprecipitation experiments proteins on western blots were analysed using 
the TrueBlot western blot kit (Rockland) as per the instructions. Membranes were washed 
with 0.05% TBS-Tween 20 and then blocked using the TrueBlot Blocker provided in the kit 
for 2 hours at room temperature. The membranes were washed again with TBS-Tween 20 
and incubated with primary antibody in blocking buffer overnight at 4˚C. Primary antibodies 
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included anti-human PAX3 (rabbit polyclonal, 1:400, Abcam), anti-acetyl-lysine (rabbit 
polyclonal, 1:500, Abcam), anti-phospho-serine (rabbit polyclonal, 1:500, Abcam) and anti-
ubiquitin (rabbit polyclonal, 1:500, Abcam). Membranes were then washed with TBS-Tween 
20 and incubated with TrueBlot anti-rabbit IgG secondary antibody (1:1000, Rockland). Blots 
were then washed with TBS-Tween 20.   
Probed membranes were visualised by chemiluminescence using the substrate provided in 
each kit (Westernbreeze and Trueblot). The substrate was mixed according to the kit 
instructions and then added to the nitrocellulose membrane and incubated for 5 minutes at 
room temperature. The nitrocellulose membrane was sandwiched between transparent 
overhead sheets and placed into a cassette. In the dark room, x-ray film (Kodak) was placed 
onto the nitrocellulose membrane and exposed for various times (30 seconds, 1 minute, 3 
minutes, 5 minutes, 10 minutes and overnight). After exposure, the medical x-ray film was 
placed in developer solution for 2 minutes and agitated, washed with water and then placed 
in fixer solution for 2 minutes, washed (water) and air dried.  
Membranes were then stripped using Restore Western Blot Stripping Buffer (Thermo 
Scientific) for 15 minutes and re-probed for β-actin by incubating with anti-actin antibody 
(rabbit polyclonal, Abcam, 1:1000) overnight at 4˚C. The western blot was performed using 
the anti-rabbit Westernbreeze kit (Invitrogen) and viewed by chemiluminescence as 
previously described.  
The levels of expression of each protein were assessed by densitometry using the GS-800 
Calibrated Densitometer (Biorad), which compares the density of the individual protein 
bands in each lane to that of β-actin in the same lane. Each sample was run as a biological 
replicate.  
 
6.8 Post-translational modifications of PAX3 proteins (phosphorylation, 
acetylation, and ubiquitination) 
 
Immunoprecipitation and western blotting were performed to assess the phosphorylation, 
acetylation and ubiquitination status of PAX3 in all cell types, as previously described (Ichi et 
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al., 2011). Briefly, cultured cells were lysed and nuclear proteins extracted as described 
above in section 6.7. PAX3 proteins were immunoprecipitated with mouse monoclonal anti-
PAX3 antibody (DSHB, 10µg/ml), which recognises the C-terminus region of the protein, or 
rabbit polyclonal (Abcam, 2.5µg/ml) or goat polyclonal (Abcam, 2.5µg/ml) antibody, which 
both recognise the common N-terminus of each of the PAX3 isoforms. The antibody/antigen 
complex was immunoprecipitated using protein A (for mouse and rabbit antibodies) or G 
(for goat antibody) magnetic Dynabeads (Life Technologies) or anti-IgG (for rabbit antibody) 
agarose beads (Rockland). Both direct and indirect methods of immunoprecipitation were 
performed to determine the most optimal procedure. The direct method involved 
incubating the immunoprecipitating antibody (mouse monoclonal anti-PAX3 (DSHB), rabbit 
polyclonal anti-PAX3 (Abcam) or goat polyclonal anti-PAX3 (Abcam)) with the appropriate 
beads (protein A or G magnetic Dynabeads (Life Technologies), rabbit anti-IgG agarose 
beads (Rockland)) for 30 minutes at room temperature. For immunoprecipitation using 
protein A or G magnetic beads, the antibodies were cross-linked to the beads using BS3 
cross-linking agent (Thermo Scientific) for 15 minutes at room temperature before 
incubating the bead/antibody complex with the protein sample. The indirect method, using 
the same antibodies and beads, included incubating the antibody with the protein first, then 
incubating the antibody/protein complex with the beads.  
Beads were washed in 250µL 1xPBS and centrifuged at 2500xg for 2 minutes (centrifugation 
was for agarose beads only). Proteins were eluted from the bead/antibody complex by 
heating samples at 70˚C for 10 minutes with 20µL glycine elution buffer (glycine buffer was 
used for magnetic beads only), sample reducing agent (1x) and sample buffer (1x) and then 
the mixture was run on a NuPAGE Bis-Tris precast gel. The following antibodies were used 
for western blotting: anti-PAX3 (mouse monoclonal, DSHB, 1:1000), anti-phosphoserine 
(rabbit polyclonal, Abcam, 2.5µg/ml), anti-acetyl-lysine (rabbit polyclonal, Abcam, 2.5µg/ml) 
and anti-ubiquitin (rabbit polyclonal, Abcam, 2.5µg/ml). Similarly, immunoprecipitation was 
performed with the anti-phosphoserine, anti-acetyl-lysine and anti-ubiquitin antibodies and 
anti-PAX3 (mouse monoclonal, DSHB, 1:1000) was used to probe the membrane (or 
precipitated proteins). Table 2 outlines important information regarding the binding sites 
and suppliers of the antibodies used throughout the western blot and immunoprecipitation 
procedures.   
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Table 2: The amino acid epitopes and catalogue numbers for the antibodies used in 
western blot and immunoprecipitation procedures throughout this project.  
Antibody Supplier Catalogue 
Number 
Binding site/s PAX3 transcripts 
recognised by 
antibody 
Anti-human PAX3  
(mouse),  
monoclonal 
 
DSHB 
 
N/A 
Amino acids   
 298-481,  
C-terminal region 
 
PAX3C-PAX3E 
Anti-human PAX3  
(rabbit),  
polyclonal 
 
Abcam 
 
ab50193 
Amino acids 
 181-230,  
N-terminal region 
 
PAX3C-PAX3H 
Anti-human PAX3  
(goat),  
polyclonal 
 
Abcam 
 
ab15717 
Amino acids 
 2-12, 
N-terminal region 
 
PAX3A-PAX3H 
Anti-acetyl lysine 
(rabbit),  
polyclonal 
 
Millipore 
 
AB3879 
Acetylated lysine residues on 
proteins 
 
N/A 
Anti-phosphoserine 
(rabbit),  
polyclonal 
 
Millipore 
 
AB1603 
Phosphoserine, 
peptidylphosphoserine, serine-
phosphorylated proteins 
 
N/A 
Anti-ubiquitin 
(rabbit),  
polyclonal 
 
Millipore 
 
07-375 
Ubiquitin and ubiquitinated 
proteins 
 
N/A 
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6.9 PAX3 silencing and analysis of PAX3 downstream targets in 
melanoma cell lines and primary melanocytes  
 
To assess whether PAX3 does indeed regulate the selected downstream target genes, PAX3 
was silenced using siRNA and RT-qPCR was performed using the primers provided in Table 1. 
The genes studied (Table 1) were chosen based on data showing them all to be regulated by 
PAX3, as well as being expressed in melanocytes and melanoma cells.  
Knock-down of all PAX3 transcripts was accomplished using pre-designed PAX3-specific 
Silencer Select siRNA (s10059 and s224172, Ambion), and Lipofectamine 2000 Transfection 
Reagent (Life Technologies) following the manufacturer’s recommendations. Briefly, 1x105 
(for melanoma cells) or 2x105 (for melanocytes) cells were seeded in a six-well plate 24 
hours prior to transfection with 10nM of PAX3-specific siRNA (s10059 and s224172 
individually, or in combination), or negative control siRNA (Negative Control #1 siRNA, 
Ambion) using RNAiMAX Transfection Reagent (Ambion). Each silencing experiment also 
included positive control, transfection with Silence Select GAPDH siRNA (Ambion), as well as 
non-treated cells. Efficient PAX3 knock-down was confirmed after 24, 48 and 72 hours post-
transfection by RT-qPCR and western blot as previously described (section 6.7). The changes 
in the expression of previously identified PAX3 targets, following its knock-down, were then 
analysed by RT-qPCR and quantified by calculating the fold change (∆∆Ct) of the gene, first 
relative to 18S (∆Ct) and then to the negative control siRNA (∆∆Ct). A threshold of greater 
than 70% knockdown of GAPDH and PAX3 using siRNA was considered a valid knockdown 
(Hsieh et al., 2004; Krueger et al., 2007). Each silencing experiment was performed in 
duplicate using biological replicates. 
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7. Results 
 
A panel of five metastatic and six primary melanoma cell lines, one neonatal and two adult 
melanocyte cultures were analysed for PAX3 expression. The levels of PAX3 mRNA and PAX3 
protein were assessed in each cell line using RT-qPCR, immunocytochemistry and western 
blot. One representative cell line from the primary and metastatic melanoma groups was 
chosen for further analysis of PAX3 transcript expression profiles and for analysis of PAX3 
post-translational modifications and downstream targets. To identify differences in PAX3 
expression between melanocytes and melanoma cells that would explain the previously 
observed differences in regulation of downstream target genes, RNAseq was used to 
compare expression profiles of PAX3 transcripts, whereas immunoprecipitation was 
performed to test for differences in post-translational modifications of the PAX3 protein 
isoforms. Finally, PAX3 silencing was used to confirm differences in the regulation of known 
downstream target genes between primary and metastatic melanoma cells and neonatal 
and adult melanocytes.  
 
7.1 Clarifying consistency of PAX3 expression within groups of cell lines 
 
7.1.1 PAX3 expression analysed by immunocytochemistry 
 
Figure 15 shows the expression of PAX3 in a panel of primary and metastatic melanoma cell 
lines and in neonatal and adult primary melanocyte cell cultures. Mouse anti-PAX3 (DSHB, 
1:50) primary antibody followed by anti-mouse IgG-550 (Dylight, 1:500) secondary antibody 
were used to stain PAX3 protein. Nuclei were stained with DAPI to confirm nuclear 
localisation of PAX3 in all cell types.  
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Immunocytochemistry results show that PAX3 is expressed in all of the melanoma cell lines 
and both neonatal and adult melanocytes (Figure 15). Furthermore, 90-95% of cells were 
PAX3 positive in all cell types. 
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Figure 15: Immunocytochemistry of neonatal and adult human epidermal melanocytes, five metastatic melanoma cell lines and 
six primary melanoma cell lines. Nuclear PAX3 protein expression (red) is observed in all melanoma cell lines and primary 
melanocytes. Cell nuclei are stained with DAPI (blue). The scale measures 100µM. A negative control was included with each 
experimental run and proved negative in each instance.   
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7.1.2 PAX3 expression analysed by Reverse-Transcriptase Polymerase 
Chain Reaction (RT-qPCR) 
 
In order to quantify PAX3 mRNA expression, RT-qPCR was performed in all primary and 
metastatic melanoma cell lines and neonatal and adult primary melanocytes (Figure 16).  
 
Figure 16: RT-qPCR was performed on six primary and five metastatic cell lines and 
neonatal and adult normal human epidermal melanocytes. The relative level of expression 
of PAX3 compared to housekeeping gene GAPDH was calculated by the ∆∆Ct method. All 
PCRs were performed in triplicate for each of two biological replicates and average values 
were used to calculate fold change over GAPDH for each sample. All samples were run in 
biological duplicates and the average fold change values are calculated and presented in 
the graph. The error bars represent the standard deviation of the biological replicates.  
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Figure 16 represents the relative expression of PAX3 for each of the primary melanoma cell 
lines (MM200, MM229, MM329, MM540, MM622 and WM115), metastatic melanoma cell 
lines (A2058, M14, SKMEL2, SKMEL5 and UACC62) neonatal human epidermal melanocytes 
(NHEM-n) and adult human epidermal melanocytes (NHEM-a (P) and NHEM-a (I)). A Mann-
Whitney U test was utilised to determine whether there was a significant difference in PAX3 
mRNA expression between cell lines of the same cell type. The primary cell line with a 
significantly lower PAX3 expression than the others was MM622 (p= 0.007). Additionally, 
the M14 cell line exhibited a significantly higher expression of PAX3 mRNA than the other 
metastatic melanoma cell lines (p= 0.007).  
To statistically compare the relative expression levels per cell type, a test for normality was 
performed, but indicated that the data was not normally distributed, thus a non-parametric 
Kruskal-Wallis test was required for further statistical analysis. Upon comparison of relative 
PAX3 expression between primary melanoma, metastatic melanoma and melanocyte groups 
using the Kruskal-Wallis test, a significant difference in PAX3 mRNA levels was found 
between groups (p=0.035). In order to determine which of the groups were significantly 
different from the others, Mann-Whitney U tests were performed. Whereas the levels of 
PAX3 mRNA in the primary melanoma group of cell lines were not significantly different 
from those in the metastatic group of cell lines (p=0.644), there was a significant difference 
in mRNA levels between primary melanoma cells and melanocytes (p=0.001). There was a 
significant difference in PAX3 mRNA levels between the metastatic group of melanoma cell 
lines and the melanocytes (p=0.002) (Table 3). Furthermore, it was found that there was a 
significantly higher expression of PAX3 in the adult melanocytes, both NHEM-a (P) and 
NHEM-a (I), compared to the neonatal melanocytes (p=0.006, p=0.004, Table 3).  
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Table 3: mRNA levels of PAX3 in melanocytes, primary melanoma cells and metastatic melanoma cells 
 
 Melanocytes Primary melanoma Metastatic melanoma 
Cell line/culture NHEM-n NHEM-a 
(P) 
NHEM-a 
(I) 
MM200 MM229 MM329 MM540 MM622 WM115 A2058 M14 SKMEL2 SKMEL5 UACC62 
Mean fold change (x10
-3
) 
Std dev (x10
-3
) 
52.16 
±22.33 
909.28 
±56.65 
208.84 
±5.31 
13.09 
±7.33 
1.99 
±0.20 
5.01 
±2.55 
8.68 
±4.14 
1.10 
±0.09 
6.35 
±0.05 
4.51 
±3.09 
22.95 
±16.15 
10.97 
±7.15 
3.32 
±1.22 
3.59 
±2.27 
Between group  
p-values  
(Kruskal-Wallis test) 
Melanocytes v Primary 
melanoma: p= 0.001* 
 
Melanocytes v Metastatic 
melanoma: p= 0.002* 
Primary melanoma v Melanocytes: p= 0.001* 
 
Primary melanoma v Metastatic melanoma: p= 0.644 
Metastatic melanoma v Melanocytes: p= 0.002* 
 
Metastatic melanoma v Primary melanoma: p= 0.644 
*Statistically significant, p ≤ 0.05 
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7.1.3 Western blot 
 
Western blot was used to determine the relative levels of PAX3 protein in all cell types. For 
each sample, a standard amount of protein (20µg total nuclear protein) was loaded onto the 
gel. The levels of PAX3 protein in each of the six primary melanoma cell lines, five metastatic 
melanoma cell lines, one primary neonatal melanocyte culture and two adult melanocyte 
primary cultures were assessed.  
 
 
Figure 17: Western blot results. Each sample was run in duplicate on each of two 
biological replicates on separate gels and blotted against PAX3 (DSHB, 1:1000) and β-actin 
(Abcam, 1:1000). The representative western blots are shown here. 
 
The western blot (Figure 17) revealed a single band when blotted with anti-PAX3 antibody 
(mouse monoclonal, DSHB) of around 55kDa. This corresponds to isoforms PAX3C, D and/or 
E which are 53kDa, 53kDa and 56kDa, respectively. Furthermore, primary melanoma cell 
line WM115 also showed a band around 44kDa, which could correspond to isoforms PAX3G 
or PAX3H. PAX3 protein levels were assessed by densitometry to quantitatively assess 
expression levels relative to that of β-actin and the average fold change above that of β-
actin for each sample was graphed (Figure 18).  
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Figure 18: PAX3 protein expression relative to β-actin expression. Each sample was run in 
duplicate on separate gels and the density of each band was assessed by densitometric 
scanning using the GS-800 Calibrated Densitometer (Biorad). The density of each PAX3 
band was compared to that of the housekeeping gene β-actin for each lane on the same 
membrane and the fold change calculated and graphed. The error bars represent the 
standard deviation between duplicate samples.  
 
Densitometry results were normalised to the background and PAX3 protein expression was 
calculated relative to β-actin. The data were normally distributed and so a one-way ANOVA 
was used to compare relative PAX3 protein expression levels between groups. There was no 
significant difference in relative PAX3 protein expression between the primary melanoma 
cell lines, metastatic melanoma cell lines or melanocytes when the groups were compared 
using a one-way ANOVA test (p= 0.088, Table 4). Furthermore, a student’s T-test was used 
to determine whether there was significant difference in PAX3 protein expression within 
each of the groups. There was no significant difference in relative PAX3 protein expression 
between the primary melanoma cell lines, however, within the metastatic melanoma cell 
line panel, PAX3 protein was significantly higher in M14 than in A2058, SKMEL5 and UACC62 
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(p= 0.037, p= 0.035 and p= 0.032, respectively). Comparison of PAX3 protein expression 
within the melanocyte cells showed no statistically significant difference. These results differ 
considerably to the results obtained from qPCR analysis of mRNA expression, where the 
PAX3 mRNA expression in adult melanocytes was significantly higher than that found in the 
primary and metastatic melanoma cell lines and neonatal melanocytes.  
Primary melanoma cell line MM540 and metastatic melanoma cell line M14 were chosen for 
further comparative experiments along with neonatal (NHEMn) and adult (NHEMa (I)) 
primary melanocyte cultures.   
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Table 4: Protein levels of PAX3 in neonatal and adult melanocytes and primary and metastatic melanoma cells 
 
 Melanocytes Primary melanoma Metastatic melanoma 
Cell line/culture NHEMn NHEMa 
(P) 
NHEMa 
(I) 
MM200 MM229 MM329 MM540 MM622 WM115 A2058 M14 SKMEL2 SKMEL5 UACC62 
Mean and standard 
deviation 
1.415 
±0.254 
1.369 
±0.257 
1.700 
±0.149 
1.405 
±0.283 
0.857 
±0.136 
1.179 
±0.195 
1.632 
±0.162 
1.543 
±0.292 
1.063 
±0.013 
1.417 
±0.034 
1.730 
±0.046 
1.487 
±0.028 
1.145 
±0.020 
1.359 
±0.028 
Between group  
p-values  
(one-way ANOVA) 
Melanocytes v Primary 
melanoma: p= 0.331 
 
Melanocytes v Metastatic 
melanoma: p= 0.901 
Primary melanoma v Melanocytes: p= 0.331 
 
Primary melanoma v Metastatic melanoma: p= 0.482 
Metastatic melanoma v Melanocytes: p= 0.901 
 
Metastatic melanoma v Primary melanoma: p= 0.482 
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7.2 RNAseq to assess differential expression of PAX3 transcripts 
 
One representative cell line from each of the melanoma cell groups, as well as one neonatal 
and adult melanocyte primary culture, were analysed by RNAseq for relative PAX3 transcript 
expression profiles. Total messenger RNA from metastatic melanoma cell line M14, primary 
melanoma cell line MM540, neonatal normal human epidermal melanocytes (NHEMn) and 
adult normal human epidermal melanocytes (NHEMa, Promocell) was sequenced using 
paired end sequencing on the Illumina HiSeq2000 platform at the Australian Genome 
Research Facility.  
Primary data analysis was conducted by the Australian Genome Research Facility. Primary 
sequence data was generated using the Illumina CASAVA 1.8.2 pipeline as a FASTQ format. 
Cleaned sequence reads were aligned against the human genome using the Tophat aligner 
and transcripts were assembled with the Cufflinks tool using the reference annotation based 
assembly (RABT) option. Differential expression of the PAX3 transcripts was then analysed 
through the use of Cufflinks applications Cuffmerge and Cuffdiff, merging the two samples 
for comparison and assessing the differential expression of the transcripts. Each of the 
transcript expression levels were normalised to the highest expressed transcript level and 
the fold change for each transcript and significant difference of transcript expression 
between cell types was calculated.   
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Figure 19: A comparison of PAX3E expression levels between neonatal and adult 
melanocytes and MM540 and M14 melanoma cell lines measured as number of reads per 
kilobase of exon model per million mapped fragments. Asterisk (*, **) denotes significant 
difference. No significant difference was found between neonatal melanocytes and the 
primary or metastatic melanoma cell lines. 
 
Adult melanocytes were compared against neonatal, primary and metastatic melanomas. 
The only PAX3 transcript shown to exhibit significant differential expression between cell 
types was PAX3E, which was significantly downregulated in primary and metastatic 
melanoma cells compared to adult melanocytes (Figure 19), with a significant fold change of 
4.28 between metastatic melanoma cells (M14) and adult melanocytes (NHEMa) (p<0.001), 
and a significant fold change of 4.58 between primary melanoma cells (MM540) and adult 
melanocytes (NHEMa) (p<0.001). There was no statistically significant difference between 
PAX3 transcript expression profiles between neonatal and adult melanocytes.   
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7.3 Testing for post-translational modifications 
 
7.3.1 Optimisation of immunoprecipitation procedure 
 
In order to ensure optimal immunoprecipitation procedures, a number of optimisation 
conditions were trialled in order to find the most effective immunoprecipitation method. 
Optimisation steps included testing direct versus indirect methods, the use of different anti-
PAX3 antibodies, different temperatures for antibody-antigen binding, as well as different 
incubation times, and different immunoprecipitation beads.  
As indicated below, the direct immunoprecipitation procedure failed to capture the PAX3 
protein, evident from the bands present in the lane containing the supernatant (lanes 3, 5, 7 
and 9), whilst no bands were present in the lanes containing the immunoprecipitated 
sample (lanes 2, 4, 6 and 8, Figure 20A). Furthermore, it was not possible to determine 
whether PAX3 was immunoprecipitated by the indirect procedure due to the presence of 
the antibody heavy chains at 50 kDa, which could mask the presence of PAX3 protein at 56 
kDa (lanes 2, 6 and 8, Figure 20B). It was apparent, however, that any of the three bead 
types (ChIP, protein A or protein G) could be used in further immunoprecipitation 
experiments, as they produced the same result, or lack of it (lanes 2-5 and 6-9, Figure 20B).     
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Figure 20: Optimisation of the immunoprecipitation procedure using direct (A) and 
indirect (B) procedures. Temperature (4˚C) and incubation times (overnight) were kept 
constant. Anti-PAX3 antibodies raised in mouse and goat were used and ChIP beads and 
protein A (mouse) and G (goat) beads were also tested. The supernatant (the flow-
through that was collected after incubation of the beads, antibody and protein) was run 
alongside each immunoprecipitation sample to determine whether the PAX3 antibody 
sufficiently immunoprecipitated the PAX3 protein. mPAX3, rPAX3 and gPAX3 = PAX3 
antibody raised in mouse, rabbit and goat respectively.  IP = immunoprecipitation, Sup. = 
supernatant. 
 
Due to the presence of multiple bands in the indirect immunoprecipitation procedure, the 
direct method was used to determine the optimal concentrations of the 
immunoprecipitating antibody (using mouse, rabbit and goat anti-PAX3 antibodies). 
Concentrations of 1μg and 10μg of antibody were used along with protein A (mouse and 
rabbit) and protein G (goat) coated Dynabeads (Invitrogen) to immunoprecipitate PAX3. 
Again, the result showed that PAX3 was not being pulled out of the total nuclear proteins by 
the bead and antibody complex, despite changing the concentration of the antibody (Figure 
21). 
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Figure 21: Optimisation of the direct immunoprecipitation procedure using different anti-
PAX3 antibody concentrations (1μg or 10μg) to immunoprecipitate the PAX3 protein. 
Protein A (mouse and rabbit) and protein G (goat) Dynabeads were used for 
immunoprecipitation. mPAX3, rPAX3 and gPAX3 = PAX3 antibody raised in mouse, rabbit 
and goat respectively.  IP = immunoprecipitation, Sup. = supernatant. 
   
Due to the absence of PAX3 protein in the lanes containing the immunoprecipitated sample 
when the direct method was used, it was clear that the indirect method should be used for 
further optimisation.  Further experiments were conducted using anti-PAX3 antibodies 
raised in different species for immunoprecipitation and western blot (Figure 22A). Antibody 
heavy and light chains appear when only the antibodies were used in the 
immunoprecipitation procedure, without cellular protein (lanes 2-7, Figure 22B). The flow 
through from washing after incubation of the antibody and antigen was also included on the 
gel in order to determine whether the antibody was binding the PAX3 protein but detaching 
during washing (lanes 5 and 8, Figure 22A). 
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Figure 22: Optimisation of the immunoprecipitation procedure. A) Immunoprecipitation 
was performed using anti-PAX3 (goat) and immunoblotted with anti-PAX3 (rabbit) to 
attempt to eliminate antibody heavy chain interference, however, results indicate cross-
reactivity between species. Additionally, a band appears at 44kDa in the input when 
blotted with anti-PAX3 raised in rabbit, which corresponds to isoforms PAX3G and PAX3H 
(lane 2). B) Anti-PAX3 antibodies (mouse (m) (lanes 2 and 3), rabbit (r) (lanes 4 and 5) and 
goat (g) (lanes 6 and 7)) were subject to the IP procedure, without cellular protein, and 
blotted with mouse anti-PAX3 to determine where antibody heavy and light chains 
appeared on the gel to allow us differentiate between antibody IgG and our PAX3 
product. mPAX3, rPAX3 and gPAX3 = PAX3 antibody raised in mouse, rabbit and goat 
respectively.  IP = immunoprecipitation, Sup. = supernatant; F/T = flow through. 
 
For these reasons, after extensive optimisation of the immunoprecipitation procedures, the 
indirect method was chosen for all further analyses, along with anti-PAX3 raised in rabbit as 
the immunoprecipitating antibody and anti-PAX3 raised in mouse as the immunoblotting 
primary antibody, due to its lower background. Anti-PAX3 raised in mouse was unable to be 
used as the immunoprecipitating antibody as it produced multiple bands when 
immunoblotted with anti-PAX3 raised in both rabbit and mouse.  
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7.3.2 Immunoprecipitation and western blot 
 
Total nuclear proteins were extracted from the metastatic cell line, M14, and the primary 
melanoma cell line, WM115, as well as from neonatal (NHEMn) and adult (NHEMa (I)) 
melanocytes, and subject to immunoprecipitation using anti-acetyl lysine, anti-
phosphoserine and anti-ubiquitin antibodies, respectively. Mouse anti-PAX3 antibody was 
then used to blot the membranes to determine if PAX3 was included in the proteins that 
were acetylated, phosphorylated or ubiquitinated. 
 
 
 
Figure 23: Immunoprecipitation (IP) using anti-acetylysine (AL), anti-phosphoserine (PS) 
and anti-ubiquitin (Ub) immunoblotted with anti-PAX3 (mouse monoclonal, DSHB) in the 
metastatic melanoma cell line M14 (A), the primary melanoma cell line WM-115 (B), adult 
human epidermal melanocytes (NHEM-a (I)) and neonatal human epidermal melanocytes 
(NHEM-n) (C). Figure 23D shows the presence of a 44kDa product using M14 cell lysate 
and immunoblotting with mouse anti-PAX3 antibody (DSHB). Al= acetylated, PS = 
phosphorylated, Ub = ubiquitinated;  mPAX3, rPAX3 and gPAX3 = PAX3 antibody raised in 
mouse, rabbit and goat respectively.  IP = immunoprecipitation, Sup. = supernatant.   
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Post-translational modifications of PAX3 were analysed in the metastatic cell line M14 
(Figure 23A). Lane 1 contains M14 total nuclear protein input, blotted using anti-PAX3 
(mouse monoclonal, DSHB) for comparison with other sample lanes. Each precipitating 
antibody (anti-PAX3, anti-acetylysine, anti-phosphoserine and anti-ubiquitin) was run 
alongside its respective immunoprecipitation (IP) sample to confirm the presence of the 
desired product relative to the presence of antibody heavy chains (at approximately 50kDa). 
Lanes 3, 5, 7 and 9 contain the immunoprecipitated PAX3 protein, acetylated proteins, 
phosphorylated proteins and ubiquitinated proteins, respectively. The membrane was then 
blotted for PAX3 and, after ruling out the product being the heavy chain of the antibody, it 
can be seen that a product that measures approximately 56kDa is present in each of the 
immunoprecipitation lanes, which could correspond to PAX3 isoform E (56 kDa), or 
potentially PAX3C and/or D (53 kDa). This result suggests that these isoforms are acetylated, 
phosphorylated and ubiquitinated in the M14 metastatic melanoma cell line. 
PAX3 protein from the primary melanoma cell line, WM-115, was also tested for acetylation, 
phosphorylation and ubiquitination using the respective antibodies, as described above. As 
shown in Figure 23B, upon immunoprecipitation with the anti-acetyl lysine, anti-
phosphoserine and anti-ubiquitin antibodies and imunoblotting with anti-PAX3, a product of 
44kDa, corresponding to the expected size of PAX3g and PAX3h isoforms, suggests that 
these isoforms are possibly acetylated, phosphorylated and ubiquitinated in primary 
melanoma cell line WM115, whereas a band of 56kDa was not detected.  
Furthermore, PAX3 acetylation, phosphorylation and ubiquitination were assessed in both 
the adult primary melanocytes and the neonatal primary melanocytes (Figure 23C). Again, a 
product of 44kDa is present in each of the samples, whereas a band of 56kDa was not 
detected, suggesting that PAX3g or PAX3h are acetylated, phosphorylated and ubiquitinated 
in normal human epidermal melanocytes. Although a 44kDa band is not detected in the 
input in Figures 23B and 23C, previous western blot results have detected a product of 
44kDa in the input using the mouse anti-PAX3 monoclonal antibody when exposed for a 
longer period of time (e.g. Figure 23D). 
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Interestingly, it appears that there is the possibility of different isoforms of the PAX3 protein 
being differentially post-translationally modified in the metastatic melanoma cell line 
compared to those of the primary cell line and neonatal and adult melanocytes. 
7.4 PAX3 silencing and downstream targets 
 
PAX3 silencing was used to confirm the differential regulation of previously identified 
downstream target genes by PAX3 in primary and metastatic melanoma and adult and 
neonatal melanocytes.  The expression levels of each of the downstream target genes were 
calculated by normalising the Ct value of the gene to that of 18S (ΔCt). The fold change in 
siPAX3 was then calculated relative to the negative control siRNA sample (ΔΔCt), and 
converted to a percentage, and this was performed for each of the four cell types over the 
course of a three day silencing experiment. The knockdown experiment included GAPDH 
silencing as a positive control to ensure that the procedure was effective (Figure 24).  Once 
the efficacy of the procedure was confirmed, PAX3 silencing was performed on neonatal 
and adult melanocytes and primary and metastatic melanoma cells and downstream target 
gene expression was analysed by qPCR. 
Figure 24 shows a dramatic knockdown of GAPDH in primary melanoma (WM115) (>98%) 
and metastatic melanoma (M14) (>78%) cells following treatment with GAPDH siRNA, 
indicating that the knockdown procedure was effective in these two cell lines. PAX3 was 
also sufficiently silenced in the primary melanoma cells (>75%), however, knockdown of 
PAX3 in the metastatic melanoma cells was not efficient following treatment with PAX3 
siRNA (<56%). Primary melanocyte cultures did not show efficient knockdown of either 
GAPDH or PAX3 after treatment with siRNA, with adult melanocytes showing <50% 
knockdown of GAPDH levels and <52% knockdown of PAX3 levels, and neonatal 
melanocytes showed <57% and <40% GAPDH and PAX3 knocked down, respectively. 
Although the knockdown procedure was not considered efficient for the adult and neonatal 
melanocyte cultures (with knockdown of GAPDH <70%), remaining PAX3 expression was 
significantly lower than negative controls in all cell types following treatment with siPAX3 
and therefore downstream target gene expression was analysed further.  
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Figure 24: Percentage of remaining mRNA expression of PAX3 following silencing with siPAX3 and GAPDH following silencing 
with siGAPDH in adult melanocytes, neonatal melanocytes, primary melanoma cells and metastatic melanoma cells. 
Percentage of remaining mRNA expression was calculated relative to 18S and then as fold change relative to the negative 
control (NC) siRNA and converted to a percentage. si DAY 1, 2, 3  = Day 1, 2, 3 of GAPDH or PAX3 silencing experiments; si 
DAY 1, 2, 3 NC = Day 1, 2, 3 of negative control silencing experiments run in parallel to GAPDH and PAX3 silencing. Each 
silencing experiment was performed in duplicate using a biological replicate.  
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7.4.1 Expression levels of PAX3 downstream targets involved in 
cell differentiation following PAX3 silencing 
 
Figures 25-28 represent the percentages of remaining mRNA expression of PAX3 and those 
of its downstream target genes relative to the negative control in each of the four cell types, 
after knockdown of PAX3 with siRNA.  Percentage of remaining expression was analysed by 
RT-qPCR at 24, 48 and 72 hours following transfection with siRNA to silence PAX3. 
Following transfection of cells from all cell types with PAX3 siRNA, PAX3 was shown to be 
significantly (but not efficiently) decreased post-knockdown in neonatal (NHEMn, p=0.045) 
and adult (NHEM (I), p=0.046) melanocytes, and in primary (WM115, p<0.05) and metastatic 
(M14, p=0.020) melanoma cells (Figure 25). 
Furthermore, MITF was shown to be downregulated in neonatal melanocytes after PAX3 
siRNA transfection (p=0.027) and in the primary and metastatic melanoma cell lines 
(p=0.004; p=0.033, respectively). Although MITF expression levels in adult melanocytes 
were not significantly reduced following PAX3 silencing, there is a trend toward lower MITF 
expression levels post-silencing. DCT also exhibited a significant and striking decrease in the 
primary metastatic cell line only following silencing of PAX3, (p<0.05). NES is significantly 
downregulated in primary melanoma cells after PAX3 silencing (p=0.029), and, HES1 
expression is downregulated only in neonatal melanocytes after transfection with PAX3 
siRNA (p=0.017) (Figure 25). These findings indicate that differentiation genes are not 
generally affected by PAX3 in metastatic melanoma cells, even though PAX3 was effectively 
knocked down in these cells. Although two biological replicates were included, the lack of 
knockdown of MITF and other differentiation genes in adult melanocytes after silencing of 
PAX3 was not surprising considering the lack of effective PAX3 inhibition in these cells and 
additional experiments are required to confirm this.  
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Figure 25: Remaining expression levels (%) of PAX3 downstream targets MITF, DCT, HES1, SOX9 and NES in adult (NHEM (I)) and 
neonatal (NHEMn) melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3 
knockdown with siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control (siNC) 
and converted to a percentage. Asterisk (*) indicates significant difference, p≤0.05.  siPAX3 –D1, 2, 3 = Day 1, 2, 3 of PAX3 silencing 
experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3 silencing. Each silencing 
experiment was performed in duplicate using a biological replicate.
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7.4.2 Expression levels of PAX3 downstream targets involved in 
cell proliferation following PAX3 silencing 
 
The results in Figure 26 show the percentage of remaining expression of CCNA2 and TPD52, 
genes involved in cell proliferation, after transfection of cells with PAX3 siRNA. The results 
indicate that CCNA2 is significantly downregulated in adult melanocytes following PAX3 
knockdown (p<0.05). By contrast, primary and metastatic melanoma cells express 
significantly less TPD52 after PAX3 knockdown (p=0.021, p=0.004, respectively). These 
findings suggest that key cell proliferation genes are differently regulated by PAX3 in adult 
melanocytes and primary and metastatic melanoma cells. 
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Figure 26: Expression levels (%) of PAX3 downstream targets CCNA2 and TPD52 in adult (NHEM (I)) and neonatal (NHEMn) 
melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3 knockdown with 
siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control (siNC) and 
converted to a percentage. Asterisk (*) indicates significant difference, p≤0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of PAX3 silencing 
experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3 silencing. Each 
silencing experiment was performed in duplicate using a biological replicate. 
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7.4.3 Expression levels of PAX3 downstream targets involved in 
cell survival following PAX3 silencing 
 
When analysed after transfection of cells with PAX3 siRNA, the metastatic melanoma cell 
line showed significant downregulation of BCL2L1 expression (p<0.05) on the second day 
post-transfection (Figure 27). Interestingly, BCL2L1 expression was significantly higher on 
days 1 and 3 post-transfection (p<0.05). The primary melanoma cell line exhibited a 
significant decrease in PTEN mRNA expression post PAX3 silencing (p=0.046) (Figure 27). 
Thus, PAX3 potentially differentially regulates genes responsible for cell survival in primary 
and metastatic melanoma cells compared to melanocytes.  
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Figure 27: Expression levels (%) of PAX3 downstream targets BCL2L1, PTEN and TGFβ1 in adult (NHEM (I)) and neonatal 
(NHEMn) melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3 
knockdown with siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control 
(siNC) and converted to a percentage. Asterisk (*) indicates significant difference, p ≤ 0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of 
PAX3 silencing experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3 
silencing. Each silencing experiment was performed in duplicate using a biological replicate.
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7.4.4 Expression levels of PAX3 downstream targets involved in 
cell migration following PAX3 silencing 
 
The CXCR4 gene was the only cell migration gene that was shown to be downregulated 
following PAX3 silencing, particularly in neonatal melanocytes (p= 0.016) and in the primary 
melanoma cell line (p= 0.013) (Figure 28).  
In summary, PAX3 knockdown caused a dramatic and significant decrease in genes 
associated with differentiation in primary melanoma cells, but less so in metastatic 
melanoma cells.  Moreover, different proliferation genes were associated with PAX3 
knockdown in melanocytes relative to melanoma cells, confirming previous work indicating 
differential regulation of these pathways in melanocytes relative to melanoma cells.  
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Figure 28: Expression levels (%) of PAX3 downstream targets MCAM, CSPG4 and CXCR4 in adult (NHEM (I)) and neonatal 
(NHEMn) melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3 
knockdown with siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control 
(siNC) and converted to a percentage. Asterisk (*) indicates significant difference, p≤0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of 
PAX3 silencing experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3 
silencing. Each silencing experiment was performed in duplicate using a biological replicate.
  
  
* * 
* 
* 
* 
* 
 70 
 
8. Discussion 
 
The overall aim of this project was to confirm the regulation of selected downstream target 
genes by PAX3 and to determine the mechanism of their differential regulation in 
melanoma cells compared to melanocytes. It was hypothesised that differential regulation 
results from different PAX3 alternate transcript expression or different post-translational 
modifications of the protein in these cells.  
We showed here that there are indeed differences in PAX3 expression in melanocytes and 
melanoma cells. Firstly, we identified a discrepancy between PAX3 mRNA and protein levels 
in adult melanocytes, indicating that ubiquitination or miRNA activity play a role in PAX3 
regulation in these cells. Furthermore, we found that PAX3 transcript expression profiles 
differ in melanoma cells compared to melanocytes. Our results also suggested that PAX3 
protein isoforms undergo different post-translational modifications in metastatic melanoma 
cells compared to melanocytes. Lastly we demonstrated that selected downstream target 
genes are indeed regulated by PAX3, with some of these downstream targets being 
differentially regulated in melanocytes compared to melanoma cells.  
Given the significant role of PAX3 in melanocyte development, and the significant 
expression of PAX3 in melanoma, the role of PAX3 in melanoma cells needs to be 
comprehensively clarified. The outcomes of this study further our understanding of the role 
of PAX3 in melanoma and ultimately, through further research, may lead to PAX3 becoming 
a target for therapeutic treatment. 
8.1 PAX3E expression is downregulated in melanoma cells compared to 
melanocytes 
 
One way in which downstream target genes of PAX3 could be differentially regulated is 
through alternate transcript expression. Each of the PAX3 transcripts has been shown to 
produce a protein with a different function. Our data from RNA sequencing revealed that 
the PAX3E transcript is expressed at significantly lower levels in metastatic and primary 
melanoma cells compared to adult melanocytes (Figure 19). The role of PAX3E is thought to 
 71 
 
be to reduce proliferation of melanocytes and to increase apoptosis (Wang et al., 2006). If 
PAX3E is downregulated in primary and metastatic melanoma cells, this could result in an 
increase in the proliferation of melanoma cells and a decrease in activation of apoptosis 
pathways, resulting in melanoma progression. This needs to be further investigated using 
additional cell lines and confirmed in melanoma tissue samples. Moreover, confirmation of 
a decrease in PAX3E protein should be confirmed in melanoma tissue samples with PAX3E 
specific antibodies.  
Further research is also required to identify a mechanism whereby the action of this 
individual PAX3 isoform may influence melanomagenesis, perhaps giving melanoma cells 
the ability to proliferate, migrate, survive and maintain a “stem cell-like” state as in 
melanoblasts. 
8.2 Differential PAX3 acetylation, phosphorylation and ubiquitination 
in metastatic melanoma cells compared to primary melanoma cells 
and melanocytes 
 
Another way that PAX3 could differentially regulate downstream target genes is through 
post-translational modifications. Previous research has demonstrated acetylation, 
phosphorylation and ubiquitination of PAX3 in neuroblasts and myoblasts, causing these 
precursor cells to differentiate into their pre-determined adult forms (Boutet et al., 2010; 
Boutet et al., 2007; Dietz et al., 2011; Ichi et al., 2011; Miller et al., 2008). Our results 
suggest that PAX3 possibly undergoes acetylation, phosphorylation and ubiquitination in 
adult melanocytes, neonatal melanocytes, primary melanoma cells and metastatic 
melanoma cells, however, the isoforms that undergo these modifications differ between 
metastatic melanoma cells relative to the other three cell types. Our results show that the 
acetylated, phosphorylated and ubiquitinated PAX3 product in the metastatic melanoma 
cell line could be one, or a combination, of PAX3C, PAX3D and/or PAX3E isoforms. By 
contrast, the primary melanoma cell line and adult and neonatal melanocytes have isoforms 
PAX3G and/or PAX3H, with post-translational modifications.  
Thus it is possible, from our results, that different PAX3 isoforms are postranslationally 
modified in metastatic melanoma cells compared to primary melanoma cells and 
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melanocytes and this could be one important mechanism by which differential downstream 
target gene regulation occurs in metastatic melanoma cells. Interestingly, neonatal 
melanocytes seem to lack ubiquitination of all PAX3 isoforms, indicating that all isoforms are 
possibly required at maximal levels during this time period. The presence of differential 
protein modifications in the four cell types could explain the differential regulation of 
downstream target genes in these cells, leading to differences in cellular function and 
phenotype and may contribute to the differential regulation of pathways associated with 
melanoma. 
Different PAX3 isoforms possesses different amino acid residues and thus different sites at 
which acetyl, phosphate and ubiquitin moieties can attach (Boutet et al., 2010; Boutet et al., 
2007; Dietz et al., 2011; Ichi et al., 2011; Miller et al., 2008). Although the sites for 
acetylation, phosphorylation and ubiquitination have been identified in PAX3, not all PAX3 
isoforms possess all of these sites.  
Acetylation of the PAX3 protein has been demonstrated by Ichi, et al. (2011) to occur at 
lysine residues 437 and 475 of the PAX3 protein. More recently, potential acetylation sites 
have been discovered at lysine residues 107, 116, 182 and 183 (Figure 29)(Cell Signaling 
Technology). Isoforms PAX3G and PAX3H contain only the more recently discovered 
potential sites for acetylation, while isoforms PAX3C, PAX3D and PAX3E contain both sites 
required for acetylation. Since acetylation of the isoforms will only increase their molecular 
weight by a maximum of 252Da (if all six sites are acetylated), which is not separable by SDS-
PAGE, it is indeed possible that PAX3 isoforms C, D and/or E are differentially acetylated in 
metastatic melanoma cells, affecting downstream target gene regulation. 
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Figure 29: Additional potential sites of acetylation on the PAX3 protein (lysine (K) residues 
107, 116, 182 and 183) (Cell Signaling Technology). 
 
Previous research has demonstrated that acetylation of PAX3 causes it to repress, rather 
than activate, the same promoter on downstream target genes (Ichi et al., 2011). Since 
alternate PAX3 isoforms differentially regulate cellular function (Wang et al., 2006). , and 
these isoforms are potentially variably acetylated, it is plausible that differential acetylation 
of these isoforms differentially regulate cellular function, adding a layer of complexity in the 
role of PAX3 regulation of downstream target genes. 
Serine residues 201, 205 and 209 of the PAX3 protein are possible sites of phosphorylation 
(Dietz et al., 2011; Miller et al., 2008). Isoform PAX3A does not contain serine residues at 
positions 201, 205 and 209 and therefore evades phosphorylation at these sites. The 
remaining PAX3 isoforms (PAX3B-PAX3I) do possess these identified sites for 
phosphorylation.  
Posttranslational phosphorylation of PAX3 is actioned by GSK-3β (glycogen synthase kinase 
3 beta) and CK2 (formerly casein kinase II) (Dietz et al., 2011; Kubic et al., 2012). Inhibition 
of GSK-3β results in a decrease in PAX3 expression in melanoma cells thereby altering 
proliferation states and regulation of apoptosis and terminal differentiation (Kubic et al., 
2012). It is possible that the differential phosphorylation of PAX3 by GSK-3β could alter 
these cellular processes through either degradation of the protein, similar to that which has 
been shown with β-catenin (Aberle et al., 1997), or stabilisation and activation of the 
protein and alteration of its function via activation or repression of downstream targets 
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(Takeda et al., 2000a; Zeng et al., 2005). Again, the alternate PAX3 isoforms have the 
potential to differentially regulate cellular functions and this could be achieved through the 
variable phosphorylation of PAX3 isoforms, as we have demonstrated here, which could 
lead to differential activation or repression of downstream target genes.  Here, we 
identified that between each of the cell lines, several downstream target genes of PAX3 
were differentially regulated. Furthermore, PAX3 was found to be differentially 
phosphorylated in metastatic melanoma cells compared to primary melanoma cells and 
adult and neonatal primary melanocyte cells cultures. Thus, it is possible that 
phosphorylation of the PAX3 protein contributes to differential downstream target gene 
regulation. 
Ubiquitination of the PAX3 protein occurs at the same lysine residues as acetylation (K437 
and K475) (Boutet et al., 2010; Boutet et al., 2007), meaning that, like acetylation, 
ubiquitination of isoforms PAX3C, PAX3D and PAX3E can occur. Ubiquitination of the PAX3 
protein enables it to be recognised by the proteosomal degradation pathway and, at the 
required time during development, has been shown to cause cells to differentiate (Boutet et 
al., 2010; Boutet et al., 2007). This indicates that PAX3 degradation would remove its 
activation or repression of downstream target genes and the differential ubiquitination of 
PAX3 isoforms could be a mechanism underpinning differential downstream target gene 
regulation.  
Ubiquitin moieties would increase the molecular weight of the protein by up to 52.8kDa if 
all six possible lysine residues are ubiquitinated, a size difference separable by SDS page. 
Since our suspected product has the same molecular weight as acetylated and 
phosphorylated PAX3 in primary and metastatic melanoma cells and adult melanocytes, it is 
possible that fewer sites on the PAX3 protein are ubiquitinated in these cell types.  
Although PAX3 isoforms are shown to be ubiquitinated in metastatic melanoma, primary 
melanoma and adult melanocytes, they appear not to be so in neonatal melanocytes. There 
is however no significant difference in PAX3 protein levels between these four cell types, so 
it is possible that the PAX3 isoforms ubiquitinated in these cell types are not the 
predominant forms or all PAX3 isoforms are not ubiquitinated and this is evident from our 
results.  
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Real-time qPCR and western blot analyses on each of the cell lines and primary melanocytes 
were performed to confirm PAX3 expression in all of these cell types. However, from these 
results, it can be seen that there is a discrepancy between the levels of mRNA and protein in 
adult melanocytes (Figures 16 and 18, respectively). RT-qPCR results show that PAX3 is 
expressed at significantly higher levels in adult melanocytes, while PAX3 protein levels in 
adult melanocytes do not differ significantly from those of primary or metastatic melanoma 
cells. Although this was not an expected finding from our research, it supports our 
hypothesis that there is differential regulation of PAX3 in melanocytes relative to melanoma 
cells and this is possibly by ubiquitination. Furthermore, our results indicate that PAX3 
ubiquitination is not present in neonatal melanocytes. By contrast it is present in primary 
and metastatic melanoma and adult melanocytes, however different isoforms are 
ubiquitinated. Ubiquitination of PAX3 in adult melanocytes may therefore contribute to the 
lower PAX3 protein levels in these cells.  
PAX3 is ubiquitinated differently in melanoma and melanocyte cells, meaning it is possible 
that the PAX3E isoform is differentially lost in these cells, influencing downstream pathway 
regulation. However, although the PAX3E mRNA transcript is downregulated in melanoma 
cells, this is not evident in overall PAX3 protein levels, since there is no significant difference 
in protein levels between cell types.  A difference in levels of this protein may not be evident 
on its own, or the difference in mRNA levels may not translate to differences in protein 
levels and further research is required to demonstrate differences in PAX3E protein levels in 
the different cell types, where differences may be due to ubiquitination.  
Changes in mRNA and protein expression are generally attributable to ubiquitination or 
regulation by miRNA. To date, the miRNAs shown to regulate Pax3 expression in the 
myogenic lineage are miR-1, miR-27b and miR-206, particularly in embryonal and alveolar 
rhabdomyosarcoma (Li et al., 2012) and could possibly regulate PAX3 expression in 
melanoma. In addition miR-211 has been associated with melanoma, and is shown to 
repress an upstream regulator of PAX3, BRN2 (Boyle et al., 2011). miR-211 is reduced in 
melanoma cell lines in comparison to melanocytes and overexpression of miR-211 in 
melanoma cell lines inhibits cell invasion (Boyle et al., 2011). In this way, it is possible that 
other miRNAs exist that have the potential to regulate PAX3. 
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8.3 Knockdown of PAX3 differentially downregulates key genes 
involved in cell differentiation, proliferation, migration and survival 
in melanoma cells compared to melanocytes 
 
Previous research conducted by our group identified 13 potential downstream target genes 
of PAX3, several of which were differentially regulated in melanoma cells compared to 
melanocytes (Medic et al., 2011). In order to further clarify the role of PAX3 in melanoma, 
regulation of these genes in different cell types of melanocytic lineage were assessed 
following PAX3 silencing and then downstream target gene expression was analysed. 
Ultimately, the aim was to confirm the regulation of these genes by PAX3 in normal 
melanocytes, through primary melanoma cells, to metastatic melanoma cells and to 
determine whether PAX3 plays a role in cell migration, proliferation, survival and 
differentiation in all of these cell types through regulation of specific target genes.  
MITF is a key gene involved in melanocyte differentiation, survival and proliferation 
(Watanabe et al., 1998). Our results indicate that MITF expression following PAX3 silencing 
is decreased significantly in primary neonatal melanocytes and melanoma cells and, 
although not significant, trends toward lower expression in adult melanocytes. This suggests 
that PAX3 regulates MITF in melanocytes and melanoma cells. Furthermore, the regulation 
of MITF by PAX3 in neonatal melanocytes and primary and metastatic melanoma cells 
indicates that PAX3 maintains tight control of differentiation pathways in these cells to 
regulate proliferation, migration and maintenance of an undifferentiated phenotype, which, 
in melanoma cells, may contribute to melanoma progression (Cronin et al., 2009). The 
knockdown of HES1, a marker of undifferentiated cells which aids in survival of melanocyte 
precursors (Moriyama, 2006), observed here in neonatal melanocytes, confirms the role of 
PAX3 in maintenance of undifferentiated cell phenotype through this gene in melanocytes 
but not melanoma cells.  
By contrast, our results showed that in adult melanocytes, PAX3 silencing did not cause a 
significant downregulation of any of the tested genes involved in cell differentiation (MITF, 
DCT, HES1, SOX9, NES). This is presumably due to the fact that the silencing was not efficient 
or possibly that differentiation genes are not as effectively regulated by PAX3 in these 
already differentiated cells.  
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Following PAX3 silencing, only primary melanoma cells exhibited DCT downregulation. In 
normal melanoblasts, the inhibition of DCT by PAX3 causes these cells to remain in their 
undifferentiated state, allowing them to maintain their proliferation, migration and survival 
properties (Lang et al., 2005), so in primary melanoma cells, this regulation of DCT by PAX3 
could similarly maintain a relatively undifferentiated state.  
As shown previously by Wang et al. (2007), we observed regulation of CCNA2 by PAX3 in 
normal melanocytes. Notably, cell cycle regulators CCNA2 and TPD52 were differentially 
regulated in adult melanocytes and melanoma cells following PAX3 silencing. We showed 
here that PAX3 regulates CCNA2 in adult melanocytes, whereas TPD52 is regulated by PAX3 
in melanoma cells. This confirms earlier findings by Medic et al. (2011), who also showed 
differential regulation of TPD52 in melanocytes and melanoma cells. The regulation of 
TPD52 by PAX3 in melanoma cells could be one mechanism underpinning an alternative 
PAX3-driven mechanism of cell survival of melanoma cells relative to melanocytes and 
requires further investigation.  
Here we also demonstrated that PAX3 regulates two key cell survival genes in melanoma, 
while these do not appear to be controlled by PAX3 in melanocytes. BCL2L1 and PTEN are 
both downregulated in response to PAX3 silencing in melanoma cells. In particular, since 
BCL2L1 inhibits apoptosis, its regulation by PAX3 in metastatic melanoma cells may be a cell 
survival mechanism (Margue et al., 2000). PTEN is knocked down in response to PAX3 
silencing in primary melanoma cells, indicating that PTEN is regulated by PAX3. However 
regulation may be in an indirect manner, activating a separate pathway involved in PTEN 
regulation, as previously PAX3 has been shown to inhibit PTEN expression in melanoma cells 
(Li et al., 2007). Furthermore, PTEN has previously been shown to be differentially regulated 
in melanoma cells compared to melanocytes (Medic et al., 2011).  
The variable results demonstrated in differential downstream target gene regulation limit 
the efficacy of this experiment. The presence of very few significantly downregulated 
downstream target genes in neonatal and adult melanocytes may be attributable to the 
insufficient knockdown of PAX3. Although the silencing procedure was tested for efficiency 
using siGAPDH as a positive control, and GAPDH was found to be sufficiently knocked down 
in adult and neonatal melanocytes, it is possible that PAX3 silencing was not as effective in 
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these cells due to their slow turnover rate. Alternately, other potential downstream target 
genes are differentially regulated by PAX3 in melanocytes, thus further investigation is 
needed, in more samples and possibly in tissues, in order to gain an improved 
representation of the role of PAX3 in regulating these downstream target genes.  
In summary, in this project, we have demonstrated PAX3 regulation of downstream target 
genes that drive key pathways in cell differentiation, proliferation, migration and survival. 
Furthermore, we have shown that this regulation differs in melanocytes relative to 
melanoma cells and that this differential regulation could be attributable to alternate 
transcript expression, shown through the downregulation of PAX3E in melanoma, or 
differential protein modifications of the PAX3 isoforms.  
8.4 Limitations of the study and suggested future experiments 
 
The most significant limitation of this study is that all experiments were performed in one 
cell line per cell phenotype limiting the general applicability of these findings. Additional 
experiments in additional cell lines for each phenotype in vitro and in tissue are required to 
further identify the role of PAX3 in differential activation of downstream target genes. There 
is however only one commercially available neonatal cell line and very few adult melanocyte 
primary cell cultures, limiting what is possible in vitro.   Alternately, additional experiments 
could be conducted using tissue explants or fresh tissue samples to gain a more 
comprehensive understanding of the complex role of PAX3 in skin homeostasis and in 
melanomagenesis. 
Different antibodies against PAX3 preferentially recognise and bind to different PAX3 
isoforms. When used for immunoprecipitation and western blotting, this contributed 
significantly to difficulties with experiment optimisation. New transcript-specific antibodies 
have recently become available commercially however these have not been confirmed in 
the literature, as useful for immunoprecipitation. Furthermore, optimisation of these 
experiments with additional cell lines, and alternative immunoprecipitation kits with a range 
of PAX3 antibodies, is required to further our understanding of these isoforms. 
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The lack of change in downstream target gene regulation indicated by our results suggests 
that either these genes do not depend on PAX3 for their regulation, or more likely, 
insufficient PAX3 silencing prevented us from observing any effect on the target. This means 
that further silencing experiments in these cell types is required to determine whether PAX3 
was sufficiently knocked down and whether the results acquired are a true representation 
of these cell types. The limited number of biological replicates reduces confidence in the 
PAX3 silencing data and therefore an increase in the number of biological replicates is 
required for each cell line. In order to increase the efficiency of PAX3 knockdown in 
melanocytes, the transfection procedure should take place over 48 hours, rather than the 
24 hour time lapse used here. It is possible that the inefficient knockdown of PAX3 is due to 
the slow turnover of melanocytes compared to melanoma cells. Improving the efficiency of 
this experiment will enable us to determine which downstream target genes are 
differentially regulated in melanocytes compared to melanoma cells and will help to 
broaden our understanding of the mechanisms underpinning differential downstream target 
gene regulation in melanoma cells compared to melanocytes.  
Additionally, immunoprecipitation of the individual PAX3 isoforms, using specific antibodies, 
followed by assessment of the isoforms for differential post-translational modifications in 
melanoma cells compared to melanocytes will further our understanding of the individual 
roles of the PAX3 isoforms in melanoma compared to normal skin melanocytes.   
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9. Conclusion 
 
In conclusion, melanoma is an extremely aggressive skin cancer and is highly drug resistant 
(Chen et al., 2006; Chin et al., 2006), emphasising the need to define mechanisms involved 
in the development and progression of this cancer so as to make advances in the 
therapeutic treatment of melanoma. Previous research has demonstrated that potential 
downstream target genes of PAX3 are differentially regulated in metastatic melanoma 
compared to normal human epidermal melanocytes (Medic et al., 2011). We hypothesised 
that this differential regulation of downstream targets by PAX3 could be attributable to 
alternate PAX3 transcript expression or differences in post-translational modifications of the 
PAX3 protein between metastatic melanoma cells and normal adult human melanocytes. 
Thus, we assessed the PAX3 transcript expression, PAX3 post-translational modification 
profiles and the regulation of downstream target genes in normal human adult and 
neonatal melanocytes relative to primary and metastatic melanoma,  
Here we have identified that the PAX3E transcript is downregulated in metastatic and 
primary melanoma cells compared to normal adult human melanocytes. Since the role of 
PAX3E in normal melanocytes is to reduce proliferation and increase apoptosis (Wang et al., 
2006), our results suggest that its downregulation in melanoma could be one of the 
mechanisms underpinning the ability of melanoma cells to evade apoptosis and increase cell 
proliferation. Furthermore, we have shown that PAX3 is regulated at a post-translational 
level in normal adult and neonatal melanocytes and in primary and metastatic melanoma 
cells, with differential modifications of PAX3 isoforms in metastatic melanoma cells 
compared to normal melanocytes and primary melanoma cells. Moreover, we showed that 
PAX3 in normal neonatal human melanocytes is not ubiquitinated, in contrast to the other 
three cell types, confirming differential regulation of PAX3 at different developmental 
stages. Finally, we have confirmed differential regulation of downstream target genes 
involved in differentiation, proliferation, migration and cell survival between normal human 
adult and neonatal melanocytes, and primary and metastatic melanoma cells. 
The major limitation of this study was the apparent preferential binding of the PAX3 
antibodies to different isoforms, making it difficult to immunoprecipitate the PAX3 protein 
and effectively visualise it using western blotting. Thus, future experiments should look into 
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using isoform specific antibodies that have recently become commercially available. 
Furthermore, silencing experiments need to be repeated and expanded to include more 
samples, in order to confirm differential regulation of downstream targets between 
melanocytes and primary and metastatic melanoma cells. Finally, transcript expression 
profiling should be performed on an increased number of samples.  
By further analysis, the mechanisms by which PAX3 differentially regulates downstream 
target genes could become clearer, furthering our knowledge of the potential role of PAX3 
in melanoma progression. Given the importance of PAX3 in the development of 
melanocytes and its expression in the majority of melanoma cells, knowledge of differences 
in PAX3 regulated mechanisms between normal cells and melanoma cells that lead to 
melanoma progression could provide tools for therapeutic manipulation of melanoma cells 
while sparing the normal cells. 
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